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ABSTRACT 
  Cancer amounts to about 600,000 deaths per year [1]. In advanced cases of the disease, 
the tumor vasculature permits systemic circulation of tumor cells to secondary tissue sites 
resulting in metastasis. Developmental oncological drugs require testing on platforms that are 
representative of the human tumor microenvironment. Animal models offer varying signaling 
pathways that create a translational gap between testing and clinical results. Current in vitro 
testing systems do not accurately mimic the tumor microenvironment as they lack a consistent 
endothelial monolayer and controllable fluid flow. Poor quality models result in an 8% success 
rate of drugs in clinical trials [2]. We propose a novel tumor model composed of a lyophilized 
10% silk scaffold cultured with an endothelial cell monolayer in a perfusion bioreactor system 
to control fluid flow rate and mimic mechanics of a capillary. Preliminary data confirmed the 
development of a viable endothelial scaffold in a sterile, reperfusable bioreactor system, which 
is promising for future co-culture applications and in vitro oncological drug testing. 
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CHAPTER 1 -- INTRODUCTION 
Statistical analysis of United States pharmaceutical companies discovered that the 
research and development costs to produce one oncology drug exceed $650 million [3]. In 
addition to high production costs, about 85% of early stage clinical trial candidates fail before 
being tested in the clinic [4]. This high failure rate is due in part to the translational gap 
between current in vitro human tumor models and clinical performance [3]. New oncological 
drugs are currently tested using three-dimensional (3D) cell culture utilizing either a hydrogel 
scaffold or a tumor spheroid system [5]. Prior to use in human subjects, drug efficacy and 
toxicity can be analyzed in rodent models [3]. However, in addition to ethical considerations 
regarding animal use, these models fail to reflect the extracellular stromal component and 
relevant cytokine signaling pathways present in human tissue, which are important in 
promoting the vascularization of the tumor [3]. To replicate a portion of the tumor environment 
in an in vitro model, this project aimed to develop an endothelialized scaffold for future 
coculture with neuroblastoma cells. The scaffold needed to provide 3D supporting architecture 
for both the endothelial and neuroblastoma cells. Neuroblastoma cells are ideal for modeling a 
solid tumor because they are phenotypically diverse, heterogeneous, and often prone to 
metastasis due to their early onset and prevalence along major blood vessels [6]. By mimicking 
the hierarchical structure of native vasculature, the model provides a more realistic in vitro 
testing platform that better mimics a physiologically relevant tumor microenvironment, thus 
increasing preclinical data translatability and lowering attrition rate.  
 The ideal scaffold for a device of this nature is biocompatible and offers tunable 
mechanical properties. Being able to alter the mechanical properties of the scaffold is 
important when combining with the cells. The scaffold should be able to offer a high stiffness 
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(~10 kPa) and be compatible with a surface coating to ensure endothelial proliferation and tight 
junction formation [7]. Possible scaffold materials compatible with 3D culture include silk, 
collagen, synthetic polyester composite and fibronectin. The goal for the material is to provide 
a support structure for the adhesion of endothelial cells to a scaffold material to create a viable 
endothelial cell layer with tight junction occludin and claudin protein complex formation to 
establish barrier function. The barrier function mimics that of an in vivo endothelial cell layer, 
providing a more accurate model. 
This project aimed to develop a method to seed endothelial cells in a monolayer and 
ensure even distribution and tight junction formation. Available endothelial cell types include 
human umbilical vein cells (HUVEC) and TIME cells. HUVEC cells are primary endothelial 
cells that are derived from the human umbilical vein. TIME cells are an endothelial-like 
immortalized cell line derived from human foreskin. After deciding on a cell type, the 
endothelial cells were seeded in a monolayer on the silk scaffold. 
Once the cells adhered to the scaffold, the phenotype and function of the 
prevascularized cell scaffold was validated using fluorescent microscopy to characterize the 
endothelial monolayer. Staining was done using an antibody for F-actin, an essential protein 
for stress fiber formation and barrier function regulation. A metabolic viability assay using 
resazurin assessed the viability of the engineered endothelium prior to experimental use. In the 
future, the media concentration levels can be monitored to determine whether the endothelium 
can successfully regulate transport of molecules into the bloodstream. 
To support endothelial cell growth, a perfusion bioreactor was designed to recapitulate 
capillary bed blood flow and recycle cell media through the prevascularized scaffold material. 
The goal of the bioreactor system was to recapitulate the cyclic wall shear stress found in blood 
  
3 
 
vessels [8]. The mechanical stimulus provided by the perfusion bioreactor system fostered 
extracellular matrix production as well as endothelial proliferation [8]. Additionally, the 
continuous fluid flow through media reperfusion permitted high flow rates to accommodate for 
versatile scaffold geometries while eliminating the need to frequently replace cell culture 
media, ultimately reducing the total cost of model operation.  
The bioreactor system required sterilization between each use. To ensure sterilization 
capability, the materials used were made of material that can be sterilized, either via autoclave 
or 70% ethylene oxide. In addition to durability at high temperatures and moistures, the system 
functioned in an incubator to regulate the temperature of the system and ensure cellular 
homeostasis at 37 ± 0.5℃.  
From a temporal standpoint, the bioreactor needed to be able to support the 
endothelialized scaffold for at least seven days to allow for adequate cell proliferation and 
testing. To supply the tissue, the system needed to contain ports through which depleted media 
can be drained and replaced.  
After the development of the perfusion bioreactor system that effectively supports a 
prevascularized scaffold, a solid pediatric neuroblastoma cell coculture can be added to 
replicate the cytokine signaling present in the tumor microenvironment. Coculturing the model 
with cancer cells may mimic the diseased state of the endothelium, and will then be an accurate 
representation of a cancer mass on which pharmaceuticals can be tested. The endothelial cells 
could be cocultured with other tumor associated cell types, such as fibroblasts and immune 
cells, to provide a heterogeneous microenvironment that is more representative of the in vivo 
tumor. This project presents a perfusion bioreactor system that can support a functional 
endothelium with tight junction formation. In addition, the prevascularized scaffold could 
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allow for coculture with solid tumor neuroblastoma cells, creating an accurate in vitro 
endothelialized tumor model that can be used for preclinical oncology drug assays. 
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CHAPTER 2 -- LITERATURE REVIEW 
2.1 Metastatic Cancer 
Statistics estimated that in the year 2016, cancer caused 595,690 deaths in America, 
which amounts to about 1600 deaths per day [1]. Metastasis, the process by which cancer cells 
migrate from the primary site throughout the body, is the principal cause of death in cancer 
patients [9]. For many patients, by the time cancer is detected metastasis has already occurred, 
which makes it difficult to implement drug treatments that target specific cancers, therefore 
requiring the use of potent systemic treatment modalities. When cancer metastasizes to a late 
stage, surgical, chemical and radiation treatment options cannot effectively treat all tumor 
growth. Current treatments for metastatic cancer are limited and often inadequate.  
During metastasis, cancer cells detach from their primary sites in the tumor and begin 
to migrate toward lymphatic tissue or blood vessels. Upon reaching a blood vessel, the tumor 
cells must cross the endothelial barrier to enter circulation in a process known as intravasation. 
Once in circulation the metastatic cells may be attacked by the immune system or killed by the 
shear stress induced by the blood. If the cells remain viable in circulation, they are transported 
to capillaries in a secondary location.  
The site of metastatic spread can vary depending on the site of the original tumor and 
path taken through the circulatory system. Tumor cells may then undergo extravasation and 
exit the bloodstream, where they migrate into the surrounding tissue and proliferate. The newly 
formed tumors replicate and undergo angiogenesis, the formation of new blood vessels [10]. 
The process of cell metastasis and tumor formation is shown in Fig. 2.1.  
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Fig. 2.1 Schematic of intravasation of tumor cells from the epithelial tissue through the endothelium 
resulting in tumor migration to secondary tumor sites [9].  
Reprint with permission from Annual Reviews. 
 
2.1.1 Classification of Metastatic Tumors  
Cancer cells can be classified as a metastatic or a non-metastatic phenotype. Tumors 
made up of non-metastatic cells are considered benign while those tumors that consist of both 
metastatic and non-metastatic cells are considered malignant [11]. The chance of a patient 
having a malignant tumor varies widely depending on the location. For example, 80% of 
discovered breast masses are found to be non-cancerous or benign [12] while only 5-10% of 
gastric tumors are benign [13]. 
The locations of tumor origins can affect the locations to which they spread. Many 
types of cancer have organ-specific patterns of metastasis. For example, breast cancer 
frequently spreads to the bones, lungs, liver, and brain. Table 2.1 shows some of the common 
sites of metastatic tumors and their sites of spread. There are two main reasons for this organ-
specific metastasis. The first is that vascular pathways limit and control the areas to which 
  
7 
 
these tumors can spread. The second is that there is a “seed-soil” compatibility between the 
cancer cells and the location to which they are spreading [14]. Therefore, while an organ may 
lie along the vascular path of the tumor cell, that organ may not support the growth of that type 
of cancerous cell.  
Table 2.1 Common sites of metastasis [14]. 
Site of original tumor Site of spread 
Neuroblastoma Bone, lymph nodes, liver 
Breast Bone, lung, liver, brain 
Colorectal Liver, lung, peritoneum 
Lung Other lung, brain, bone, liver 
Ovary Lung, liver, peritoneum 
Prostate Liver, lung, adrenal glands, bone 
Stomach Liver, lung, peritoneum 
Bladder Lung, liver, bone 
Uterus Vagina, peritoneum, liver, lung, 
Bladder Bone, liver, lung 
Thyroid Liver, lung, bone 
Melanoma Skin, muscle, bone, brain, liver, lung 
 
2.1.2 Pediatric Neuroblastoma 
Neuroblastoma (NB) is the most common extracranial solid tumor in pediatric patients, 
representing 7% of childhood malignancies [15]. It is most common for NB to develop within 
the first year of life; however, NB may arise in adult patients at a significantly less rate of 
incidence. About 1 in 100,000 children per year are diagnosed with NB, while only 1 in 10 
million adults are diagnosed with NB annually [16]. 
NB arises from the malignant transformation of sympathetic neuroblasts, which are 
primitive neural cells [17]. It is an extremely heterogeneous cancer type, as some tumors may 
spontaneously regress while others are aggressively metastatic. NB tumors most commonly 
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develop in the adrenal glands or peripheral sympathetic ganglia then metastasize to other 
locations. The adrenal system is highly vascularized, providing increased blood vessels and 
resulting surface area for tumors to efficiently migrate throughout the body. NB is ideal for 
modeling solid tumors due to its embryonic origins, phenotypic diversity, ability and likelihood 
to metastasize, and prevalence along major blood vessels [6].  
 
2.2 Blood Vessel Anatomy and Classification  
Blood vessels can be divided into three categories: arteries, capillaries, and veins. 
Arteries transport oxygenated blood from the heart throughout the body and veins carry 
deoxygenated blood back to heart [18]. Of these vessels, capillaries primarily deliver oxygen 
and nutrients to tumor masses in the epithelial tissue. Gas and nutrient exchange between the 
blood and surrounding tissue occurs in capillary vessels that are located in structures referred 
to as capillary beds, which can be seen in Fig. 2.2 [18]. Capillary vessels do not exceed 4-9 μm 
in diameter and contain a thin, flat layer of cells known as endothelial cells which create a tight 
barrier between the blood vessel lumen and surrounding tissue [19]. These permeable vessels 
allow for the selective transport of nutrients from the bloodstream to major organ systems and 
tissues of the body.  
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Fig. 2.2 Diagram indicating blood transport of oxygenated and deoxygenated blood and capillary mediated 
flow through major organ systems [18].  
Reprint with permission from OpenStax. 
 
2.2.1 Protein Junction Complexes of the Endothelium 
 Endothelial cell adhesion and communication are modulated by three types of protein 
complexes known as gap junctions, adherens junctions and tight junctions [20]. Gap junctions 
are composed of connexin proteins that modulate ion transfer for intercellular communication 
within the endothelium [21]. Adherens junction proteins are dominated by vascular 
endothelial-cadherin (VE-cadherin) which provide a site for endothelial cell attachment and 
adhesion to one another [22]. These complexes, seen in Fig. 2.3, are concentrated around the 
basal lamina to facilitate adhesion of the endothelial cells to the basal membrane and secure the 
endothelium [20]. Tight junctions consist of claudin, occludin and other protein units anchored 
by actin filaments in the endothelial cells [20]. These proteins are responsible for regulating 
barrier function across the endothelium. Disruption of these complexes results in increased 
permeability of the endothelium [20]. Tight junctions also influence migration of leukocytes 
from the bloodstream to the surrounding tissue [22]. Leukocytes, or white blood cells, circulate 
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to areas of infection or inflammation to facilitate an immune response [22]. In disease states 
the extravasation of leukocytes can inhibit endothelium function due to the induced disruption 
to the endothelial intercellular junctions [20]. 
 
  
Fig. 2.3 Tight, gap and adherens protein complex structures in endothelial cells [19]. 
Reprint with permission from Elsevier. 
 
2.2.2 Endothelial Barrier Function 
 Endothelial tight junctions consist of claudin, occludin and JAM protein complexes 
[23]. These protein complexes serve as transport complexes and ion channels that can regulate 
permeability into the blood vessel lumen. Integral proteins within the tight junction complex 
possess the ability to determine size and charge of ions attempting to cross the membrane [23]. 
Endothelial transport favors small molecules with no charge. Therefore, disruption of the pH or 
concentration of surrounding molecules can influence the behavior of the tight junctions [23].  
 Several extracellular proteins interact with the protein complexes and can support the 
function of both adherens junctions and tight junctions. Among these adhesive proteins within 
the extracellular lumen of the endothelial layer, platelet endothelial cell adhesion molecule 
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(PECAM) contributes to the integrity of endothelial barrier function [22]. Current knowledge 
of the mechanism of action of PECAM is limited to its role in cell anchorage in the basal 
lamina. 
Extracellular proteins such as PECAM support tight junctions through cytokine 
signaling interactions and pathways. However, the mechanism of how the protein transmits 
signals in extracellular space is unknown [22]. Murine gene expression experimentation 
demonstrated that animals expressing inactivated PECAM proteins exhibited increased 
endothelial permeability over the control indicating that PECAM signaling influences the 
structure and function of endothelium [20]. PECAM complexes and other integral proteins 
associated with tight junction formation can be modified in response to cytokine signaling 
pathways. One major pathway that influences endothelial cell growth and differentiation is the 
angiogenesis pathway in response to low oxygen conditions in vivo [23].  
F-actin contributes to the structural integrity of the tight junction. In a confluent 
endothelial monolayer, F-actin is expressed around the individual cell perimeter. This actin 
ring is referred to as cortical actin which provides structural stability to the protein junction 
[24]. In addition, stress fibers composed of F-actin form within endothelial cells and provide a 
location for protein adhesion [24]. Essential tight junction proteins adhere to the surface of the 
actin making actin essential in endothelial permeability [24].  
2.2.3 Hypoxia in the Tumor Microenvironment 
 Hypoxia is the deprivation of oxygen in living tissue. The rapid metabolism and 
proliferation of tumor cells consumes more oxygen than the existing vasculature can supply to 
the tumor environment, resulting in hypoxia. In response to these low oxygen levels, hypoxia 
signaling pathways initiate to promote angiogenesis and restore oxidative balance to the target 
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area [25]. These pathways can be seen in Fig. 2.4. The transcription factor hypoxia inducible 
factor 1 (HIF-1) dictates the major mechanisms responsible for maintenance of oxygen 
homeostasis. Oxygen regulation is modulated by the alpha domain of the HIF-1 transcription 
factor [23]. In the presence of sufficient oxygen levels, HIF-1 degrades via proteasome activity 
at the alpha subunit and does not initiate transcription of angiogenesis pathway cytokines [23]. 
 
Fig. 2.4 Hypoxia response for angiogenesis in the tumor microenvironment [26].  
 
 In low oxygen conditions (between 0.5% and 6% oxygen), HIF-1ɑ does not degrade 
and the transcription factor enters a state of activation [26]. Once activated, expression of 
growth factors occur which includes but are not limited to, ephrins, platelet derived growth 
factor (PDGF), angiopoietin 1 and 2, vascular endothelial growth factor (VEGF) and basic 
fibroblast growth factor (bFGF) [26]. The interaction of these cytokine signals contributes to 
increased endothelial cell proliferation, chemotaxis, and migration of newly formed vessels 
[25]. Angiogenesis actively attempts to restore homeostasis to keep the rapidly dividing tumor 
oxygenated. As angiogenesis accelerates to support the growing tumor the production of 
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excessive and damaged endothelium increases [26]. The defective endothelium increases 
permeability of the cell layer and increases the chances of tumor cell intravasation into the 
bloodstream.  
2.2.4 Intravasation 
Intravasation, the entry of cells into lymphatic or blood vessels, is a process that is 
important for normal cells as well as tumor cells. Intravasation is necessary during 
development, immune response, and signaling [27]. During normal intravasation, vessel 
structure and integrity is maintained due to the retention of tight junctions. However, this is not 
always the case for tumor intravasation which may result in altered endothelial phenotypes and 
the disruption of tight junctions. 
The majority of tumors enter circulation through blood vessels. Intravasation may be 
active or passive, depending on the structure of the vessel and the tumor microenvironment, 
and there are a number of identified molecular pathways for intravasation to occur. During 
metastasis, the tumor cells cross the endothelial cell monolayer of capillaries, as shown in Fig. 
2.5.  
 
Fig. 2.5 Schematic detailing intravasation of tumor cells into the bloodstream through the 
endothelial monolayer of capillary vessels.  
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 Several growth factors and signaling pathways such as HIF1 and downstream proteins 
are necessary for increased endothelial permeability in response to external stimuli. Although 
the proteins have been identified, the exact mechanisms of these effects are not fully defined 
[26]. As a result, blood vessel tumor models and culture techniques have been explored as a 
means for preclinical drug testing as well as in academia to better understand the mechanisms.  
 To account for the lack of specificity of chemotherapeutic treatments, some treatments 
use, among other things, the targeting of angiogenesis signaling pathways to prevent the 
growth of vasculature to support tumor tissue [22]. These anti-angiogenic agents are 
characterized into either monoclonal antibodies, synthetic VEGF receptors or tyrosine kinase 
inhibitors (TKI) [22]. Bevacizumab is a monoclonal antibody with affinity for the VEGF 
receptor; binding to these receptors inhibits the downstream blood vessel formation [22]. 
Synthetic high affinity VEGF receptors have been developed as a potential method of 
preventing activation of VEGF mediated angiogenesis and are currently in clinical trials; these 
synthetic receptors will have a higher affinity for VEGF binding than naturally occurring 
receptors, therefore preventing angiogenesis [22]. TKIs have been proposed to bind to the 
catalytic site of other downstream molecules that are involved in the angiogenesis pathway, 
such as receptor tyrosine kinases (RTKs). These pharmaceutical approaches aim to prevent 
tumor expansion by slowing or inhibiting blood vessel growth with the tumor tissue.  
2.2.5 Immune Cell Migration in the Tumor Microenvironment 
  In the initial stages of cancer cell signaling, the interaction between tumor cells and 
immune cells can result in ceased proliferation and apoptosis of cancer cells [23]. Tumor 
progression initiates an inflammatory response, which recruits immune cells such as 
macrophages and leukocytes to the tumor microenvironment [21]. During later stages of 
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cancer, neutrophils activate tumor induced cell signaling pathways by trapping the tumor and 
sending signals to recruit other types of immune cells in a typically unsuccessful attempt to 
fight the tumor. More recent hypotheses suggest that engaging inflammatory response cells, 
known as myeloid cells, can contribute to intravasation and tumor metastasis [21].  
 Macrophages localize to the tumor environment as a result of tumor growth on the 
basement membrane of the epithelial tissue [23]. These cells are among the first cells to be 
recruited to the tumor site where they adhere to the tumor and penetrate the tissue mass [21]. 
Macrophages release cytokines such as epidermal growth factor (EGF) which increases 
proliferation and vascular endothelial growth factor (VEGF). The increase in neighboring cell 
signaling, or paracrine signaling, increases both tumor growth and angiogenesis, respectively 
[23]. Thus, the presence of macrophages increases the rate of proliferation of the tumor while 
increasing blood supply to the mass which can expedite tumor metastasis.  
 Leukocytes, or white blood cells, are a type of immune cell that play an integral role in 
the inflammatory response. One type of leukocyte, known as a lymphocyte are signaled to the 
tumor microenvironment to help with the body’s innate tumor defense mechanism. 
Lymphocytes travel through the bloodstream and they can penetrate through the endothelial 
layer [23]. Lymphocyte penetration disrupts endothelial tight junctions and contributes to 
metastasis by decreasing barrier function and increasing permeability of tumor cells into the 
bloodstream [23].  
  
2.3 Tumor Model Research 
Currently, there are both in vivo and in vitro tumor models used for preclinical 
anticancer drug screening. Examples of in vivo models include: orthotopic xenografts, 3D 
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scaffold implants, and humanized models. In vitro models are commonly used as a 
prescreening model for in vivo testing. However, the more accurate the in vitro model is, the 
better the drug will test in vivo, reducing the number of animals needed for accurate results. 
Examples of in vitro models include: two-dimensional (2D) models, 3D tumor spheroids and 
3D tumor cultures. Three-dimensional in vitro models were developed to better mimic the 
native tumor environment. Each tumor model currently in use comes with its own set of 
limitations. 
2.3.1 In Vivo Models 
Some in vivo models consist of a direct injection of tumor cells into the organ from 
which the cancer being studied originated while others begin with tumor development in a 
scaffold in vitro to be implanted in vivo. The method of directly injecting tumor cells into an 
organ, commonly called an orthotopic xenograft, is performed in murine models, and offers a 
scaffold-free approach to the development of a 3D in vivo tumor model. This method exposes 
the developing tumor to a similar microenvironment to that of a native tumor. In this model, 
tumor cells are injected into the animal which allows for metastasis: however, in vivo 3D tumor 
scaffolds do not exhibit metastasis [28]. 
As mentioned earlier, this next type of in vivo model begins with the development of a 
tumor on a scaffold, which is then seeded with a cell type. The scaffold is then implanted into a 
live model, where it is able to use in vivo conditions such as cell signaling pathways to become 
a realistic model. A study performed by Girdhari Rijal, et al. implanted 2 mm porous scaffolds 
into immunodeficient mice after the scaffolds were cocultured with human breast cancer cells. 
An image depicting the implantation of the scaffolds can be seen in Fig. 2.6. After four weeks, 
the scaffolds were surgically removed from the murine models and examined. Results showed 
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that the tumor model increased in size and supported proper tumor cell growth in vivo [29]. 
  
Fig. 2.6 Illustration of the implantation of a tumor model into a mouse. This illustrates the location at which 
the scaffold was implanted into the murine model, as well as the two histological sections that were used to 
analyze the results of the study [30].  
Reprint with permission from John Wiley and Sons. 
 
In a study performed by W. Zhang et al., human umbilical vein endothelial cells 
(HUVECs) were used to preseed a scaffold implanted into eight-week-old male nude mice. 
The purpose of this study was to compare the tissue integration and vascularization rates seen 
in the scaffold in vitro versus in vivo. The scaffolds were cultured with HUVECs for seven 
days before being subcutaneously implanted into the mice for three days. It was concluded that 
blood perfusion rate, vascularization rate, tissue integration and ingrowth of seeded cells 
increased in the model that was implanted in vivo when compared to the in vitro model [31]. 
While this was not a tumor study, it provides insight into scaffold and how they behave in vitro 
versus in vivo. 
A third type of in vivo tumor model is a humanized mouse model. This type of model 
begins with an immunodeficient mouse, to which human immune function and protein 
expression is introduced. A humanized model is typically used to exhibit a more accurate 
human immune response when a tumor is introduced in vivo. These murine models are then 
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used as the recipient of a xenograft of a human tumor. However, once implanted, the human 
stroma of the tumor is quickly replaced by a mouse stroma. This means that the 
endothelialization of the human tumor in the mouse model will change to exhibit that of a 
mouse; the endothelialization of the tumor will no longer be accurate to that of a human [32].  
While in vivo tumor models have been shown to increase vascularization rates and 
endothelial cell growth when compared to early in vitro models, they also come with certain 
limitations. Animal models are expensive and can cost anywhere from $11 to $96 per mouse 
[33]. Humanized mouse models can cost upwards of $1,000 per female mouse [34]. It is also 
difficult to make large (greater than 12 mm in diameter) tumors since it is being implanted into 
such a small animal [30]. Orthotopic tumor models tend to be difficult to develop with a need 
for assistive imaging methods to monitor the growth of the tumors [28]. Using murine models 
is an acceptable form of experimental testing; however, mouse biology does not completely 
replicate human tumor biology. Limitations in animal models exist regarding their ability to 
accurately mimic human physiology and cancer metastasis resulting in an 8% success rate in 
the transition from animal models to clinical trials of cancer drugs [2]. In addition to the 
problems relating to data comparability, it is more humane to use in vitro models to minimize 
in vivo animal testing. 
2.3.2 In Vitro 2D Tumor Models 
 The most basic in vitro tumor model is a 2D model: this is a 2D platform that consists 
of a single endothelial monolayer in a culture plate. This type of model is useful in studying the 
migration of cancer cells across a membrane. When compared to other in vitro tumor models, 
the 2D model is inexpensive, and it is relatively quick to make and test, making it a valid 
option for studying the migration of the cancer cells. However, these models do not accurately 
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mimic tumor cell protein or gene expression, nor do they offer a hierarchical endothelial 
structure. Additionally, these cultures only model two dimensions of a tumor that is 3D in 
reality [35]. 
2.3.3 In Vitro 3D Tumor Spheroids 
The use of 3D tumor spheroids is an effective alternative to monolayer in vivo tumor 
modeling. These models consist of a complex 3D spheroidal aggregation of cancer cells, as 
seen in Fig. 2.7. These models can be used to see relatively accurate effects of certain drugs on 
cancer cells. Models that are currently in use have biomimetic qualities and exhibit many 
biologically accurate characteristics, such as growth kinetics, physiological nutrient supply and 
pH distribution. They also have tissue-like properties, including compactness and chemical 
gradients. Additionally, they can model cell to cell and cell to matrix interactions [36]. Current 
models also mimic interactions between cancer and stromal cells, and extracellular matrix [37]. 
 
 
Fig. 2.7 Illustration of the formation of a 3D tumor spheroid, beginning with tumor cells. These cells were 
then cultured using the hanging drop method to form 3D tumor spheroids [36].  
Reprint with permission from Elsevier. 
 
2.3.4 In Vitro 3D Synthetic Polymer and Hydrogel Tumor Models 
 In vitro 3D scaffold based tumor models are an alternative currently used to in vivo 
tumor models. These can be made of materials such as a porous synthetic polymer or hydrogel. 
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The models commonly include an extracellular matrix component [38]. When the scaffold is 
cultured with cancer cells and a hyaluronic acid hydrogel, the tumor cultures exhibit invasion 
and proliferation of the cancer cells throughout the model, which can be seen in Fig. 2.8. The 
microenvironment created by the 3D tumor model is favorable for the invasion, proliferation 
and migration of malignant cells, and accurately represents that of in vivo conditions [39]. 
 
 
Fig. 2.8 Fluorescent microscopy image of a hyaluronic acid hydrogel 3D tumor culture. In this study, cells 
were stained with phalloidin for F-actin, which shows the structure and function of the cells. These tumor 
culture cells were cultured on a hyaluronic acid hydrogel for two days [38].  
Reprint with permission from Elsevier. 
 
 One example of a 3D tumor culture is a hyaluronic acid hydrogel, which can be 
cultured with a prostate cancer cell line. These hydrogels were plated on a tissue culture plastic 
surface. Adequate cell cluster formation and viability was observed over a seven-week period. 
Then these cultures were used to test cancer therapy drugs [38]. Another example of a 3D 
tumor culture was made of a hyaluronan hydrogel, which is different from the previously 
mentioned hyaluronic acid because it lacks the acid component. This hydrogel was cultured 
  
21 
 
with a lung cancer cell line, which then formed a homogeneous distribution throughout the 
hydrogel. From there, the cultures were used to determine the efficacy of cancer therapy drugs 
[39]. 
 Another example of a 3D tumor model uses a collagen scaffold. Collagen is a very 
common protein in the body and its main function is to provide stability to many tissues. 
Collagen is extracted from both human and animal tissues to be used as a biomaterial. Due to 
collagen’s biocompatibility, controlled biodegradability and its ability to be prepared in various 
forms it is considered to be a suitable biomaterial for tissue engineering and other applications 
[40].  
2.3.5 In Vitro Limitations  
 One major drawback to an in vitro tumor model, in general, is that it does not 
accurately reflect the 3D organization of the in vivo tumor endothelial environment. While this 
is an important limitation to consider, it is also important to note that it is not practical to go 
straight to in vivo testing without first testing in vitro [31]. In vitro 3D tumor models are 
usually made from a synthetic scaffold like a hydrogel or polymer, which does not provide the 
same extracellular cues that would occur naturally in vivo. Additionally, because these models 
tend to be synthesized from biological sources, they have a composition that is variable and 
therefore irreproducible [38].  
 Another major drawback to the current in vitro tumor models is the accuracy to which 
they model the endothelial layer. Some in vitro models have been co-cultured with endothelial 
cells to mimic cell signaling [31]. However, a mixed coculture of cells does not allow proper 
endothelialization of the model. These models still lack a hierarchical endothelial structure, as 
would be seen in vivo. Some models attempt to incorporate an endothelial cell barrier; 
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however, these typically consist of an endothelial monolayer on the surface of the scaffold 
which cannot penetrate through the model to model angiogenesis [41].  
2.3.6 Microfluidic Devices 
In vitro models have been improved using microfluidic devices. Recent advances in the 
field of microfluidics allows for precise control over fluid flow in microchannel structures. The 
use of these devices has help create more physiologically precise models.  
Microfluidic systems have independently addressable channels that provide ideal 
models for capillary blood flow. Microfluidic tumor models are also being used to study tumor 
metastasis in vitro [41]. The independently addressable channels offer a significant advantage 
in that it allows for the device to have a distinct endothelial and tumor component as displayed 
in the Fig. 2.9. The separation of these components allows for tissue formation and cell 
communication between the channels of the microfluidic device. Assays of this nature have 
been used to determine the effect of various growth factors and cytokines on tumor cell 
migration and endothelial cell morphology [42]. In addition to cytokine signaling, microfluidic 
devices allow for small scale exposure to fluid shear stresses that allow for the modeling of 
endothelial cell stress response. Changes in these shear stresses affect vascular stability and aid 
in the angiogenesis of tumors [43]. These devices allow for determination of response but 
neglect to reflect the hierarchical tissue organization, such as the endothelium and common 
nutrients present in blood vessels within the body. 
  
23 
 
  
Fig. 2.9 Schematic of microfluidic system with endothelial (green), tumor (red) and ECM (gray) 
components [41].  
Reprint with permission from PNAS. 
  
2.4 Blood Fluid Dynamics  
 In order to effectively model the in vitro conditions of tumor endothelialization, 
growth, and metastasis, it is important to understand the basics of fluid mechanics so that the 
device can recapitulate capillary blood flow.  
2.4.1 Flow Characterization  
Fluids are defined as liquids and gases that are capable of motion. As these fluids move, 
they are subjected to forces within themselves, as well as from external sources such as walls 
and boundaries. Important parameters for fluid flow characterization include density (𝜌), 
viscosity (𝜇), pressure (P), velocity (V), diameter (D), radius (r), mass flow rate (?̇?), 
volumetric flow rate (𝑉) ̇ and cross-sectional area (A).  
Fluid flow is characterized as laminar, transitional, and turbulent using the 
dimensionless Reynolds number (Re). In laminar flow, the streamlines, created by flow are 
parallel to each other and do not mix or fluctuate. With transitional and turbulent flows, 
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varying levels of mixing and disturbance of streamlines are determined by the geometry, 
roughness, velocity, temperature, and type of fluid [44]. The extent of the turbulence in a flow 
pattern is quantified by the Reynolds number. The Reynolds number is the ratio of the inertial 
forces of the fluid to its viscous forces and can be represented as  
𝑅𝑒 =
𝜌𝑉𝑎𝑣𝑔𝐷
𝜇
 
where Re is the Reynold’s number, ϱ is the density of the fluid, Vavg is the average velocity of 
the fluid, D is the diameter of the tube, and μ is the viscosity of the fluid. 
For a channel, the diameter can be replaced with Rh, which is the hydraulic radius. The 
critical Reynolds number, Recr is the point at which a flow becomes turbulent. For internal 
flow in a circular pipe, this number is 2,300, and it is 500 for channel flow [44]. Thus, 
Reynolds numbers correspond to flow type as follows. For pipe flow, which is illustrated in 
2.10.a [44]: 
𝑅𝑒 ≤ 2300→ laminar flow 
2300 ≤ 𝑅𝑒 ≤ 4000→ transitional flow 
𝑅𝑒 ≥ 4000→ turbulent flow 
 
For channel flow, which is illustrated in 2.10.b [44]: 
𝑅𝑒 ≤ 500→ laminar flow 
500 ≤ 𝑅𝑒 ≤ 2500→ transitional flow 
𝑅𝑒 ≥ 2500→ turbulent flow 
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Fig. 2.10 Schematics illustrating the different types of fluid flow A) in a pipe and B) in a channel [44].  
Reprint with permission from McGraw-Hill.  
 
2.4.2 Laminar Flow in Pipes 
The velocity of a fluid varies across its flow profile because of the no slip condition. 
The no slip condition states that the velocity of a fluid at the wall of a pipe or channel is zero, 
and increases to the maximum velocity in the center. Due to this variation, it is most 
convenient to perform calculations using the average velocity (Vavg) [44]. The average velocity 
of a fluid at any given cross-section is related to the mass flow rate by the following equation, 
where ?̇? is the mass flow rate of the system, ϱ is the density of the fluid, Vavg is the average 
velocity of the fluid, and A is the cross-sectional area of the tube. 
?̇? = 𝜌𝑉𝑎𝑣𝑔𝐴 
Because of the no-slip condition, a stationary boundary layer is created along the walls of a 
pipe or channel. Since the fluid molecules are not moving, the fluid moves faster toward the 
center of the pipe, creating what is called a velocity profile [44]. Once the fluid at the center of 
the pipe reaches its full speed, the flow is considered fully developed. The entrance length is 
the measure of how far into the pipe or channel the flow becomes fully developed. In fully 
developed flow, the velocity profile, or size of the boundary layer, is consistent along the 
length of the flow, making the opposing shear stress along the wall constant everywhere [44]. 
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For laminar flow in pipes, the flow is fully developed, meaning that there is no velocity 
perpendicular to the motion of the fluid, and there is no acceleration. Because power is 
required to push fluid along the entire length of a pipe, there is a pressure drop across the 
length. This quantity is important to know so that the pump used in the system is powerful 
enough to maintain a consistent flow. The pressure drop is related to the viscosity of the fluid. 
Therefore, there would be no pressure loss in a frictionless fluid. The pressure drop can be 
expressed as  
𝛥𝑃 = 𝑃1 − 𝑃2 =
8𝜇𝐿𝑉𝑎𝑣𝑔
𝑅2
=
32𝜇𝐿𝑉𝑎𝑣𝑔
𝐷2
, or 𝛥𝑃 = 𝑓
𝐿𝜌𝑉𝑎𝑣𝑔
2
2𝐷
, 
where P1 is the initial pressure, P2 is the final pressure, μ is the fluid viscosity, L is the length 
of the tube, Vavg is the average velocity, R is the radius of the pipe, D is the diameter of the 
pipe, ϱ is the density of the fluid, and 𝑓 is the Darcy friction factor, 𝑓 =
8𝜏𝑤
𝜌𝑉𝑎𝑣𝑔
2  [44]. In a 
horizontal pipe, the volumetric flow rate can be modeled using Poiseuille’s Law and the same 
variables as defined above:  
[𝑉]̇ = 𝑉𝑎𝑣𝑔𝐴 =
(𝑃1−𝑃2)𝑅
2
8𝜇𝐿
𝜋𝑅2 =
(𝑃1−𝑃2)𝜋𝐷
2
32𝜇𝐿
=
∆𝑃𝜋𝐷4
128𝜇𝐿
 [44]. 
The Bernoulli equation relates average flow velocity, pressure, and the height (h) of an 
incompressible, non-viscous liquid. In addition to having a constant density, the flow must also 
be laminar and irrotational. The Bernoulli equation is useful when modelling flow through a 
constriction, or through varying heights with respect to gravity (g). The equation is as follows:  
𝑃1 +
1
2
𝜌𝑉1
2 + 𝜌𝑔ℎ1 = 𝑃2 +
1
2
𝜌𝑉2
2 + 𝜌𝑔ℎ2,  
where P1 is the initial pressure, ϱ is the density of the fluid, V1 is the initial velocity, g is 
acceleration due to gravity, h1 is the initial height, P2 is the final pressure, V2 is the finale 
velocity, and h2 is the final height [44].  
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2.4.3 In Vitro Blood Flow 
Blood is a non-Newtonian fluid, due to its inhomogeneous composition. It shear-thins, 
meaning its viscosity decreases with greater applied shear force [45]. Red blood cells are 
capable of deforming to fit through exceptionally narrow capillaries, giving blood its non-
Newtonian characteristics, and complicating its flow. Despite these characteristics, blood is 
often treated as Newtonian and incompressible when being modeled [45]. 
In the human body, arterial blood pressure ranges from a maximum (systolic) pressure 
of 100-140 mmHg to a minimum (diastolic) pressure of 60-90 mmHg [45]. In capillaries, this 
pressure is about 30 mmHg and 10 mmHg at the arterial and venous ends, respectively [45]. 
Because of the beating of the heart, blood flow in the body is pulsatile, which means it 
fluctuates over time as opposed to being steady. However, for simplicity’s sake, it is often 
modeled as steady for computational purposes. Additionally, flow in vessels is generally 
laminar, except in the aorta, as violent turbulent flows cause damage to red blood cells and 
other vessel components [45]. 
2.4.4 Capillary Blood Flow 
Capillaries are much smaller than the larger veins and arteries in the human body. 
Capillary walls are composed of a single layer of endothelial cells [45]. The flow of blood 
through them is much different from the blood flow through veins and arteries. There are 
approximately 1010 capillaries with radii of ~3.5 𝜇m and lengths of ~2 mm, with pressure drops 
of ~8.2 mmHg [45]. The velocity of the flow through capillaries is approximately 0.22 mm/s 
[45]. Oxygen and carbon dioxide are diffused across the walls of capillaries, resulting in 
additional flow and pressure across them.  
Due to the small diameters of capillaries and larger diameters of red blood cells, it is 
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difficult for the flow within them to be completely laminar and steady [45]. The peristaltic 
pumping of the heart results in non-continuous flow in capillaries, as well as sphincter muscles 
that only contract every few seconds to help contract feeding arterioles. Since many capillaries 
are smaller than red blood cells, bolus flow is often observed [45]. In this situation, red blood 
cells plug up the entire cross section of the vessel, and plasma is trapped between them. These 
regions move across the capillary in series containing both red blood cells and plasma, truly 
highlighting the heterogeneous composition of blood [45]. 
 
2.5 Perfusion Bioreactor 
 In order to adequately model an in vitro engineered endothelial layer, the culturing 
conditions must resemble, as close as possible, the conditions in vivo. This includes the 
environmental and fluid flow conditions discussed in earlier sections. To accommodate these 
needs, bioreactors have been used in tissue engineering to control the conditions during cell 
culture.  
2.5.1 Function/Operation 
 The primary function of a bioreactor system is to allow for the control of one or more 
environmental or operating factors that can affect the biological process [46]. This includes 
controlling of temperature, pH, CO2 levels, and the flow of nutrients to ensure the cells are in 
an environment that promotes cell proliferation, health, and activity. Bioreactor systems can 
also be used to mimic the mechanical environment that cells experience, such as the stresses 
and strains experienced during blood flow [47]. Their ability to perfuse or circulate media into 
and out of the culture vessel, in most cases, a scaffold, also benefits cell proliferation [48]. 
More specifically, in the field of tissue engineering, perfusion bioreactors are used to develop 
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in vitro models that provide biochemical and physical regulatory signals to the cells to promote 
the differentiation of the cells [46].  
There are a variety of bioreactors that differ in their configuration or in the application 
they are used for [46]. In the next section, some of the different types of bioreactor systems 
will be discussed along with their advantages and disadvantages.  
2.5.2 Bioreactor Systems Currently in Use 
 There are multiple types of bioreactor systems, from simple, one-way bioreactors to 
continuous perfusion, closed loop bioreactor systems. The simplest design uses a syringe and a 
gas permeable bioreactor bag that allows the media flow using a syringe pump and collected 
into a waste container, as seen in Fig. 2.10 [48]. Even though this system has the ability to 
perfuse media across the scaffold, it lacks the ability to recycle the media, therefore the growth 
factors, proteins, and other secreted nutrients will be wasted [48].  
Fig. 2.11 Simple perfusion bioreactor system [48].  
Reprint with permission from Elsevier. 
 
A more sophisticated bioreactor contains a culture chamber, where the scaffold is 
suspended, with a media reservoir connected in a closed loop which allows for continuous 
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perfusion of the media as seen in Fig. 2.11 [48]. Since the scaffold is suspended in the culture 
chamber, the media flows around the scaffold and fails to actively perfuse through the interior 
of the scaffold minimizing the nutrients and oxygen on the interior [48].  
Fig. 2.12 Closed loop perfusion bioreactor system [48].  
Reprint with permission from Elsevier. 
 
Another type of bioreactor that has been used is a hollow fiber bioreactor, a model of 
which can be seen in Fig. 2.12. In this system, the cells being cultured are immobilized on 
hollow capillary-like tubes, which are bundled together inside of a larger tube. It is through the 
larger tube that the media is perfused [48]. The hollow tubes allow for the capillary-like fluid 
flow that produces a shear stress on the cells that has been shown to support cell differentiation 
of certain cell types [48].  
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Fig. 2.13 Hollow fiber bioreactor system with cells grown on the outside of the fibers and media perfused 
throughout the hollow fibers [48].  
Reprint with permission from Elsevier. 
 
Lastly, the direct perfusion bioreactor, seen in Fig. 2.13. This bioreactor can perfuse the 
media through the pores and internal networks of the scaffold allowing the delivery of nutrients 
and removal of waste [48]. The advantage of this system is that the media can perfuse through 
the interior of the scaffold which increases the viability of the engineered tissue by promoting 
even distribution throughout the scaffold [48]. Flowing the media through the pores and 
internal networks of the scaffold also provides the cells with a shear stress, as mentioned 
before, that supports cell differentiation [48].  
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Fig. 2.14 Direct perfusion bioreactor system [48].  
Reprint with permission from Elsevier. 
 
2.5.3 Current Laboratory Apparatus and Limitations  
The current bioreactor system being used in the Coburn lab is a simple, one-way 
bioreactor that operates as indicated in Fig. 2.14. This bioreactor consists of a 5-mL syringe 
which, along with a syringe pump, is used to perfuse the media through the system. Tubing is 
used to connect the syringe to the scaffold holding device in the center of the system. A silk 
scaffold with neuroblastoma cells can be seeded into a porous lyophilized silk scaffold 
surrounded by a PDMS ring that is used to create a tight seal along the outside of the channel. 
The scaffold holding device tubing is connected to a 50-mL conical tube to collect the waste 
that flows through the system.  
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Fig. 2.15 Current Coburn lab bioreactor system. 
 
The main limitation with this current bioreactor system is that it does not allow for 
continuous perfusion of the media through the system which would require a large amount of 
media to achieve high flow rates. Additionally, flow rates are also limited by the diameter of 
syringe since the cross-sectional area of the syringe or tube was used to calculate the flow rate 
along with velocity. For this reason, syringe size must be a consideration when determining 
flow rates. 
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CHAPTER 3 -- PROJECT STRATEGY 
3.1 Initial Client Statement 
The initial client statement given to the team was to develop a 3D perfusable cancer 
model that can support complete endothelialization, endothelial cell growth and function. 
 
3.2 Technical Design Requirements 
The goal of this project was to develop an in vitro endothelialized tumor model that 
could mimic the tumor endothelium microenvironment. Enhancing of the physiological 
relevance of in vitro tumor models may decrease the translational gap between preclinical 
oncology drug testing and clinical performance while reducing the need for animal models. 
The design of this in vitro system was accomplished through the completion of the following 
overarching goals:  
I. Design and develop a method for scaffold endothelialization. 
II. Design and develop a perfusion bioreactor system for the endothelialized scaffolds that 
has the ability to trap migrating cells.  
The system was then evaluated according to the following sub-objectives:  
I. Characterize the fluid flow within the system. 
II. Characterize the engineered endothelium.  
 
The objectives of this project were divided according to their application to either the 
bioreactor system or the engineered endothelium tissue model. This separation was performed 
to account for the different engineering fields required to achieve each deliverable.  
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3.2.1 Objectives for the Engineered Endothelium 
Table 3.1 Objectives for the endothelium categorized by engineering discipline. 
 
Objectives 
Material Science   
Support endothelial cell and 
neuroblastoma cell growth. 
To produce a realistic hierarchy model the 
scaffold material supported endothelial and 
neuroblastoma growth and adhesion.  
Foster endothelial tight junction 
formation.  
Tight junction formation was essential to 
barrier function and integrity of the 
endothelium.  
Permit fluid flow through scaffold.  Fluid needed to be able to flow parallel to the 
endothelial layer along the scaffold to allow 
for continuous flow and constant wall shear 
stress representative of in vivo conditions.  
Mechanics  
Develop a compatible cell seeding 
device to ensure uniform endothelial 
distribution.  
Depending on scaffold geometry, a cell 
seeding device could be utilized to evenly seed 
the endothelial layer along the scaffold 
surface.  
Survive 7 days under standard 
physiological conditions. 
Tissue must withstand 7 days in vitro to 
permit endothelial cell growth and viability 
testing. 
 
  
The engineered endothelium needed to be grown initially as healthy endothelial tissue 
with established tight junctions that maintain the barrier function of the monolayer. To 
simulate this healthy state, the endothelium was grown on a scaffold that would support the 
future coculture of endothelial cells, neuroblastoma cells and potentially fibroblasts. The 
addition of neuroblastoma coculture could allow for cytokine signaling to naturally increase 
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the permeability and more accurately model the physiological changes induced on the tumor by 
the endothelium.  
 One of the major design parameters for the tumor model involved the geometry of the 
endothelial cell layer. It was necessary for the endothelial cells to form a uniform monolayer 
with established tight junction formation to regulate both transport into and out of the 
engineered model. The endothelial cells would ideally be seeded in a tubular microstructure to 
simulate the geometry of the capillaries in vivo. However, a monolayer would allow for design 
simplification and could allow for application of microfluidic channel devices. In addition to 
the endothelium geometry, the cell type chosen for this layer was an important design 
consideration. Telomerase-immortalized microvascular endothelial (Time) cells or human 
umbilical vein endothelial cells (HUVEC) were considered for the project.  
 Cell attachment and tight junction formation were essential to the effectiveness of the 
model. The scaffold material needed to support endothelial adhesion to maintain layer integrity 
upon introduction of fluid induced wall stress. The scaffold stiffness could not trigger 
phenotypic changes to the endothelium and should allow for the cells to retain a flat, confluent 
single layer. 
 Depending on the selected geometry, a compatible cell seeding device may be required. 
This device would provide mechanical rotation of the endothelium immediately following 
seeding on the scaffold material. The cell seeding device must be operated in a sterile 
environment within the biosafety cabinet and must also result in even distribution of the 
endothelium on the scaffold.  
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3.2.2 Functions of the Engineered Endothelium  
In order to accurately mimic the behavior and barrier function of blood vessels in vivo, the 
engineered endothelium required the following functions:  
1) The endothelial layer needed to exhibit a uniform distribution of cells on the surface of 
the scaffold devoid of gaps to represent the selectively permeable barrier of natural 
endothelium. The distribution of the cells on the scaffold surface was confirmed 
visually using confocal microscopy for 3D configurations. In addition to confocal 
imaging, immunofluorescent staining for f-actin to visualize the presence of tight 
junction complexes  between endothelial cells indicated confluency of the endothelium. 
2) The endothelial layer needed to form a thin, single cell layer of tissue with cells 
expressing a planar phenotype. The shapes of the cells were validated using confocal 
fluorescence microscopy to measure cell length to determine spreading due to 
mechanical force.  
3) The endothelium needed to be able to remain viable for a duration of at least one week. 
The viability of this tissue was confirmed by running a resazurin color changing assay. 
4) The endothelium needed to exhibit selective barrier function to be representative of the 
selective permeability of vascular endothelium. The ability of the tissue to regulate 
barrier function was confirmed by analyzing the formation of tight junctions. Tight 
junctions were stained for filamentous actin using phalloidin. Tight junction formation 
was validated by calculating aspect ratios of cortical actin.  
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3.2.3 Specifications for the Endothelialized Scaffold 
Table 3.2 Design constraints for endothelialized scaffold. 
Endothelialized Scaffold Constraints 
Material Science   
Elastic modulus of the scaffold 
material 
To produce a realistic hierarchy model, the 
scaffold material needed to support 
endothelial and neuroblastoma growth and 
adhesion.  
Degradation rate of scaffold 
material  
The scaffold material needed to withstand 
aqueous fluid flow for a minimum of 7 days.  
Mechanics  
Must support wall shear stress 
representative of in vivo capillary 
flow 
The endothelium needed to be able to 
maintain adhesion to the scaffold material 
under this wall shear stress to ensure 
sufficient endothelial development.  
   
 The engineered endothelial tissue needed to be grown on a scaffold that had an elastic 
modulus of approximately 10 kPa to obtain accurate endothelial cell morphology as well as a 
sealed monolayer with optimal cell junction formation [7]. The cell media needed to possess 
vascular endothelial growth factor (VEGF) to increase endothelial proliferation and stimulate 
formation of tight junctions within the monolayer to control barrier function [27]. The presence 
of tight junction formation was confirmed via staining for junction protein complexes using 
phalloidin F-actin stain. Barrier function was monitored through use of labeled proteins or 
large uncharged particles, to determine permeability of the engineered endothelium [49].  
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3.2.4 Objectives for the Perfusion Bioreactor 
Table 3.3 Design objectives for the bioreactor system. 
Bioreactor Objectives 
Mechanics  
Continuous perfusion of media  Cell media needed to be circulated through 
the scaffold continuously to supply the 
scaffold and resemble capillary flow.  
Compatibility with scaffold material  The scaffold material needed to fit in the 
bioreactor so that fluid can flow through the 
endothelium.  
Allow for disassembly Parts needed to be able to be taken apart for 
sterilization between uses.  
Possess ports for sampling of media  In order to test the viability of the scaffold 
during testing there needed to be ports that 
allow for sampling of media to test for pH and 
nutrient concentration.  
Enclosed system  The bioreactor needed to operate in an 
enclosed environment to keep the media and 
tissue component sterile.  
    
 The perfusion bioreactor supported the growth of the endothelialized scaffold. The fluid 
mechanics simulated the flow of blood through a capillary bed. The bioreactor needed to allow 
for continuous closed loop perfusion to recycle media and reduce operation costs. The tubing 
apparatus needed to allow for interchangeable parts that allow for complete media change and 
sterilization between uses. The entire system also required dimensions that allowed for 
complete operation within a standard incubator to ensure control over the cell culture 
environment.  
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3.2.5 Functions of the Perfusion Bioreactor  
 The bioreactor system allowed for extended culture of endothelial scaffolds in a manner 
that was representative of in vivo conditions which was achieved following fulfillment of the 
functions detailed below.  
1) The bioreactor permitted continuous perfusion of cell media at a constant flow rate for 
a minimum of seven days with the absence of leaks and air bubbles.  
2) The bioreactor system need to have the ability to be disassembled for sterilization 
following each use.  
3) The bioreactor needed to be operable in a standard incubator and able to be sterilized 
with ethylene oxide (EO). The tubing and scaffold holders in the design had to be able 
to maintain mechanical properties and integrity between the temperature ranges of 
23℃-37℃ ±2℃ to account for variation of the top temperatures.  
4) The bioreactor needed to be a totally enclosed system that did not expose the media or 
tissue components to non-sterile conditions.  
5) The bioreactor system needed to be easy to transport to allow for transfer between the 
biosafety cabinet for scaffold seeding and insertion and the incubator for maintenance 
of homeostasis. 
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3.2.6 Specifications for Perfusion Bioreactor  
Table 3.4 Bioreactor design specifications. 
Bioreactor Specifications 
Mechanics  
Achieve a flow rate of 126 mL/hr  Under assumptions of the current bioreactor 
dimensions under laminar flow conditions the 
flow rate needed to be at this value to provide 
a sufficient shear stress to induce endothelial 
growth without damage to the tissue. 
Function continuously for 7 days  The bioreactor system needed to be able to 
support tissue for a minimum of one week to 
allow for adequate tissue development and 
testing period. 
Tubing material must be sterilizable The parts needed to be able to withstand 
ethylene oxide (EO) to allow for sterilization 
between uses.  
Total system must be less than 
25.5”x 27”x 37”  
The bioreactor system needed to be smaller 
than a standard incubator to be compatible 
with current laboratory devices.  
The system must support a flow rate 
of 2.8 dyn/cm2  
The system must have the capability to 
support a flow rate representative of 
physiological shear stresses of capillaries. 
    
 The enclosed perfusion bioreactor system dimensions could not exceed those of a 
standard incubator to allow for control over the scaffold’s environment. Following this logic 
the system needed to be smaller than 25.5”x 27”x 37” [50]. This design aspect ensured that the 
media and scaffold were housed in an enclosed, sterile system at 37 ± 0.5℃. The system 
needed to be able to run for a minimum duration of one week. The one-week duration allowed 
for development and proliferation of the endothelium and sufficient time to run viability and 
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functionality testing using resazurin color changing assay and immunostaining staining for 
filamentous actins (F-actin) of the tight junction complexes [51].  
 The system allowed for disassembly for the purpose of sterilization and media changes. 
Ethylene oxide was the best sterilization method, as not all parts used in the bioreactor system 
could withstand the high temperatures of autoclaving. However, care needed to be taken that 
no cytotoxic reagents are left behind by the ethylene oxide. 
 The perfusion pump needed to be able to output a constant flow rate that could produce 
laminar flow throughout the bioreactor system resulting in an applied force normal to the 
endothelial surface. The flow rate should induce a wall shear stress of 2.8 dyn/cm2 [52]. This 
stress allowed for mechanoreceptors to stimulate healthy endothelial growth but should not 
produce detrimental forces on the endothelial cells. This stress induced optimal RhoA activity 
which was responsible for reorganization of extracellular matrix components. This resulted in 
the formation of the stress fibers essential for endothelial junction development [52]. 
 Fluid dynamics for the bioreactor were verified using COMSOL modeling software, 
which is explained further in section 4.2.4. The software could be used to model laminar flow 
as well as to calculate the wall shear stress on the scaffold. Using these calculations and models 
the optimal flow rate for the model was determined. This information provided constraints in 
terms of tubing diameter and perfusion pump specifications. The COMSOL software was used 
to model the geometry of the endothelial scaffold to determine the difference in flow rates and 
shear stress distribution as a result of scaffold geometry. 
3.2.7 Financial and Monetary Constraints  
  All objectives were subject to the temporal and monetary constraints of the project. All 
functional aspects of the in vitro model needed to be completed and tested prior to April 2018 
  
43 
 
to complete the final report and project presentation, which was a time constraint. Additionally, 
the bioreactor system, testing and tissue culture needed to cost less than $1,250 to meet the 
project budget. The availability of the resources needed to build the system and culture the 
cells was also a constraint for this project. 
 
3.3 Design Requirements (Standards) 
 During the creation of an endothelialized silk scaffold and a perfusion bioreactor 
system, it was important to follow a certain set of standards. This ensured that the process was 
comparable to other studies and ensured the process is repeatable. The standards can be broken 
down into the following categories: 
I.  Standards for the silk scaffold. 
II. Cell culture standards. 
III. Ethical standards. 
IV. Standards for the perfusion bioreactor system. 
3.3.1 Standards for Silk Scaffold 
Since the project used a silk scaffold, the silk was extracted in such a way that is 
reproducible. The silk fibroin used to make the scaffold was extracted according to the protocol 
defined in Appendix D, which was taken from the Coburn Lab at Worcester Polytechnic 
Institute (Worcester, MA USA). The silk was extracted from B. mori silkworm cocoons using 
sodium carbonate (Sigma-Aldrich Corp., St. Louis, MO), ultrapure water, and lithium bromide 
(Sigma-Aldrich Corp., St. Louis, MO). Water was boiled and combined with sodium 
carbonate. The cocoons were cut open and added to the boiling sodium carbonate solution, 
which removed sericin, a protein that holds together the strands of silk. After boiling for 30 
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minutes, the silk fibroin fibers were removed and cooled in ultrapure water, rinsed for 20 
minutes and dried. The dried silk fibers were dissolved in 9.3 M lithium bromide, dialyzed, and 
centrifuged. After lyophilization, the silk scaffolds were autoclaved in a dry state, inducing 
beta-sheet conformation and therefore the crystalline state of the scaffolds [53].  
The silk scaffold was prepared by lyophilization according to the lyophilization 
standards set forth by International Society of Lyophilizing. This allowed for consistency with 
other studies using lyophilization, and allowed for repetition of the experiments. Additionally, 
the unit of pressure measurement were the Pascal (Pa), as set forth by the International Society 
of Lyophilizing. This again allows for consistency and repeatability [54]. Additionally, the 
Food and Drug Administration (FDA) offers guidelines for lyophilizing (Inspection Technical 
Guides No. 43), in terms of cycle time and machine maintenance, which were also followed 
[55].  
3.3.2 Cell Culture Standards 
The in vitro nature of the project required the use of flasks for both the subculture of 
endothelial cells before seeding onto the scaffold and for seeding the endothelial cells onto the 
scaffold. The standard set forth by the International Organization for Standardization (ISO), 
ISO 24998:2008, was used. This standard sets requirements and test methods for dishes in 
terms of cell culture use. This ensures that the dish was sterile and used in an appropriate, 
repeatable manner [56].  
After seeding the endothelial cells onto the scaffold, the scaffold was imaged and 
endothelial cells were counted to ensure an appropriate amount of cells adhered to the scaffold. 
ISO/DIS 20391-1, a standard for cell counting, was followed. This specifies that cell surface 
adhesion was quantified the area density of the cells, i.e. the cell count per unit area. This 
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allows cell assay data to be normalized and allows for comparability between experiments 
[57]. 
The endothelial cells that were used are Time cells, an immortalized endothelial cell 
line. These cells were subcultured when they reach 80% confluent according to the protocol set 
forth by the American Type Culture Collection (ATCC). This states that the cells’ old media 
was removed and cells were rinsed with Dulbecco’s phosphate buffered saline (DPBS, ATCC 
30-2200). Trypsin-EDTA (ATCC PCS-999-003) was added and neutralized with 2% FBS in 
D-PBS. This was centrifuged (250 G for 10 minutes), the supernatant was removed and the cell 
pellet was resuspended in culture media, counted, plated, and incubated at 37℃ in a 5% CO2 
incubator [58].  
3.3.3 Ethical Standards 
Since the cells being considered are human cell lines rather than primary cells or stem 
cells, much of the ethical controversy associated with such studies is avoided. Additionally, 
because this project focuses on bioreactor design and the seeding of cells on a scaffold, animal 
or human subjects were not utilized. While animal or human implantation may be an eventual 
step in this research, it is not an objective of this team’s project. All cells, enzymes, and other 
materials were purchased or obtained legally and used according to industry standards, such as 
accepted cell culture techniques and testing/assay protocols [59].  
3.3.4 Standards for Perfusion Bioreactor System 
The perfusion bioreactor system that was created must be sterilized prior to use. In 
order to do this, the ISO 14937:2009 standard was followed, which sets forth general 
sterilization standards. The standard also includes validation mechanisms to ensure a device is 
sterile. For parts of the system sterilized by autoclave, ISO standard 17665-1:2006 was 
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followed. This provides requirements for using moist heat as a method to kill any 
microorganisms on the device [60, 61]. For any parts sterilized using ethylene oxide, ISO 
standard 11135:2014 outlining the use of ethylene oxide for sterilization of medical devices 
was used [62]. 
Future work with the endothelialized scaffold may include co-culturing the scaffold 
with neuroblastoma cells for efficacy testing of cancer pharmaceuticals. Because of this, ISO 
13485 standard for medical devices was followed. This defines a medical device as “a 
product...or in vitro reagent that is intended for use in the diagnosis, prevention, or treatment of 
diseases…” It is important to follow this standard to ensure the end product can be easily built 
upon [63].  
3.3.5 Standards for Microscopy Imaging  
 To ensure compatibility with confocal microscopy, the sample was limited to the 
dimensions of a standard microscope glass slide. This restricted the final endothelialized 
sample that we imaged to less than 25 mm in width and 75 mm in length [64]. In addition 
depending on the selected photofluor chosen for imaging, photo-quenching was considered. 
Each stain required an optimal wavelength to provide adequate fluorescence without inhibiting 
the response [65].  
 
3.4 Revised Client Statement 
After careful review of background information and design requirements, the client 
statement was redefined. The revised client statement is as follows:  
Design and build a perfusion bioreactor system that has the ability to support 
dynamic culture of endothelial cells on a lyophilized silk scaffold. 
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Doing so created a fully vascularized tumor model for in vitro pharmaceutical applications. 
 
3.5 Management Approach 
 In order to accomplish these objectives by April 2018 we devised a management 
approach to ensure that all necessary tasks could be accomplished to produce a functional 
endothelialized tumor model.  
3.5.1 Project Timeline 
 The following is a Gantt chart indicating the major milestones to complete the Major 
Qualifying Project and the dates by which they needed to be accomplished. The chart is broken 
down by term and illustrates the tasks accomplished by the middle and end of each term. With 
the conclusion of A Term, the needs analysis and conceptual design of the project were 
completed. During B Term, feasibility studies and modeling were accomplished as well as the 
creation of both a cell seeding device and a perfusion bioreactor system. In C Term, the created 
devices were further studied to characterize the fluid flow and the seeded endothelium. 
Additionally, the results from the studies were analyzed. The team allowed for extra time at the 
end of the project to account for any mishaps or extensions on certain tasks necessary during 
the process. Throughout the entire year, the report was written as tasks were accomplished, and 
the entire project was presented upon in D Term. 
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Fig. 3.1 Gantt chart for project design and development process. 
 
3.5.2 Objective Tree 
The following chart provides a work breakdown structure of the objectives required for 
the project. The major goal of the project, to design an endothelialized in vitro tumor model, 
was broken down into six major objectives: to determine the project need and current systems, 
to design and develop a seeding method, to design and develop a perfusion bioreactor system, 
to characterize the fluid flow in the system, to characterize the engineered endothelium, and to 
manage the progress of the project. Each of these six objectives were then broken down further 
into smaller tasks, the completion of which could be easily quantified. 
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Fig. 3.2 Work breakdown structure for in vitro endothelialized tumor model. 
 
3.5.3 Financial Statement 
 The entire project including the perfusion bioreactor system and the engineered 
endothelium needed to adhere to a total budget of $1,250. Biologics such as antibodies for 
fluorescent staining were a major cost to the project. In addition, endothelial media 
components such as growth factors and serum presented a recurrent cost for operation of the 
model. Cells were expanded from frozen laboratory stock which reduced the cost required for 
maintenance of cell culture. The current design favors low cost scaffold and coating materials. 
The tissue culture component of the project required some additional purchase of disposable 
lab equipment which included but was not limited to petri dishes, pipettes and gloves.  
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 The major cost of the bioreactor was the perfusion pump. The lab budgeted money to 
invest in a pump which was not docked from our project budget. The tubing and scaffold 
holder that was utilized in the bioreactor was made of low cost materials. Fig. 3.3 illustrates the 
estimated breakdown of the project budget.  
Fig. 3.3 Estimated financial breakdown for project budget. 
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CHAPTER 4 -- DESIGN PROCESS 
4.1 Needs Analysis 
There is a lack of cost effective, accurate in vitro tumor models available to 
pharmaceutical companies developing cancer treatments. The most accurate tumor model is 
one that is implanted into a murine model where it becomes fully endothelialized, mimicking 
natural tumor growth and development; however, this type of model gets very expensive, 
costing anywhere from $11 to $96 per mouse [33]. In addition, these models contribute to the 
translational gap between preclinical and clinical studies due to biological variation between 
animal models and humans and inefficiencies in experimental design [3]. Oftentimes animal 
models have varied cytokine signaling which alters the metabolic response to molecular targets 
[3]. In addition, clinical trials in humans are highly regulated and documented processes which 
result in incremental development and validated results. Animal trials do not adhere to the 
same regulations which can result in false positive results [3]. A meta-analysis of 
pharmaceutical clinical and animal trials revealed that failed animal results were not 
documented, leading to a 30% inflation of reported positive results [3]. As a result of this 
overestimation, only 8% of positive animal trials advance past Stage 1 human clinical trials [3]. 
Therefore, there was a need to develop a prevascularized scaffold with a hierarchical tumor 
microenvironment structure that had the ability to simulate the desired in vivo human response 
and reduce the need for animal testing.  
4.1.1 Prioritization of Tasks 
The goal of the project - to develop a 3D perfusable cancer model that can support 
complete endothelialization, endothelial cell growth and function - was broken down into eight 
technical constraints. For the purpose of prioritization, the constraints were ranked as a total 
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project rather than in the endothelium and bioreactor to determine which objectives and tasks 
held the most weight for the entire model. These constraints were then ranked using a pairwise 
comparison chart, as seen in Table 4.1. It was determined that the need for finding an ideal 
scaffold material was the most important task because the scaffold material or coating on the 
scaffold needed to support endothelial cell proliferation. Endothelial cell type was assigned the 
next highest ranking as the cell type determined the possible phenotype, media components 
and cost of device operation. The cells needed to represent in vivo function, minimize cost and 
provide high viability. Following cell type, it was necessary that the bioreactor system 
maintained a homeostatic environment, meaning that the system needed to maintain a 
temperature of 37 ± 0.5℃ and a pH of 7.3 to accurately mimic in vivo conditions. The system 
was also required to be enclosed to prevent contamination, reuse media, prevent leakage of 
cells and fluids, and to keep pressure and flow constant. 
Perfusion of the culture media was still necessary; however, it was not as important as 
the constraints previously mentioned. Controlling the rate of fluid flow was necessary to ensure 
the endothelial cells did not shear off the scaffold, so the wall shear stress needed to be 
approximately 2.8 dyn/cm2 [52]. Another less important constraint was making the perfusion 
bioreactor system reusable and able to be disassembled so multiple studies could be conducted 
in the bioreactor system. While this was a constraint for the project, it was not necessary to 
accomplish the overall goal. Overall cost of device production and operation received the 
lowest ranking out of the constraints. The function of the device was of paramount 
performance, but it was necessary that the final design minimized cost to appeal to 
pharmaceutical companies and academic research institutions over current methods. 
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Table 4.1 Pairwise comparison chart for project. 
 Cell 
Type 
Scaffold 
material 
Enclosed 
system 
Maintain 
homeostasis 
Monitor 
flow and 
pressure 
Perfusion 
of media 
Reusable and 
disassemblable 
Low 
Cost 
Total 
Endothelium 
Cell Type - 0 1 1 1 1 1 1 6 
Scaffold material 1 - 1 1 1 1 1 1 7 
Bioreactor 
Enclosed system 0 0 - 0 1 1 1 1 4 
Maintain 
homeostasis 
0 0 1 - 1 1 1 1 5 
Monitor flow and 
pressure 
0 0 0 0 - 0 1 1 2 
Perfusion of 
media 
0 0 0 0 1 - 1 1 3 
Reusable and 
disassemblable 
0 0 0 0 0 0 - 1 1 
Low Cost 0 0 0 0 0 0 0 - 0 
 
4.1.2 Technical Constraints of the in vitro Tumor Model  
The technical constraints of the project were categorized according to the 
prevascularization of the scaffold material as well as the bioreactor. It was necessary that the 
silk scaffold supported endothelial cell growth and proliferation, which was achieved at a 
stiffness of approximately 10 kPa. At this stiffness, cells exhibited a higher aspect ratio, 
meaning that they had a long, thin morphology. This morphology was indicative of that of 
endothelial cells, meaning a scaffold with a stiffness of approximately 10 kPa would allow the 
cells to exhibit accurate endothelial cell morphology [7].  
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In designing the perfusion bioreactor system, it was necessary to follow certain 
constraints. The system needed to maintain physiological conditions in a homeostatic 
environment, so it was placed into an incubator. This means that it was necessary for the 
perfusion bioreactor system to be smaller than 25.5”x 27”x 37”, standard incubator dimensions 
[50]. Additionally, the system needed to support culture and run for more than one week, 
which was the length of each study. The fluid flow and pressure needed to be monitored in the 
system because there could not be a wall shear stress over 2.8 dyn/cm2 [52].  
 
4.2 Concept Maps/Concept Designs/Prototyping/Modeling/Feasibility Studies 
4.2.1 Conceptual Designs 
 The project was broken down into six main design components. Each component was 
designed in many ways, which can be seen in Table 4.2. The scaffold could be made of 
materials such as silk, collagen, nanoparticles, synthetic polyester composite, or fibronectin. 
The material needed to be able to incorporate a collagen, fibronectin or Matrigel coating onto 
the silk to ensure adhesion of the endothelial cells. 
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Table. 4.2 Different concepts for each design function of the project. 
Design Function Possible Mean of Accomplishing the Function 
Scaffold 
Material 
Silk Collagen Nanoparticle Synthetic 
polyester 
composite 
Fibronectin  
Create flow of 
culture medium 
Peristaltic 
pump 
Centrifugal 
pump 
Diaphragm 
pump 
Gravity 
(hydrostatic 
pressure) 
 
Maintain 
Homeostasis 
Operate in an 
incubator 
Operate in a 
temperature 
regulated 
room 
   
Closed loop with 
continuous 
perfusion 
Peristaltic 
pump 
(No filter 
needed) 
    
Control Flow 
Rate and 
Pressure 
Size of 
tubing 
Valve Automated 
pump 
  
Sterilize the 
Bioreactor 
System between 
Uses 
Autoclave Ethylene 
oxide 
UV light 70% isopropyl 
alcohol 
 
 
 
 The next design component was to create a flow of culture medium, which could be 
accomplished with a peristaltic pump, centrifugal pump, diaphragm pump, or using gravity 
with hydrostatic pressure. In the body, endothelial cells would be subjected to the pulsating 
pressure of the heart, which made a peristaltic pump the best option to accurately model in vivo 
conditions. Homeostasis also needed to be maintained, which was accomplished by operating 
the perfusion bioreactor in an incubator or in a temperature regulated room or chamber. 
Because we did not have access to a temperature controlled room, operating the perfusion 
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bioreactor in an incubator was the only option for this project. The perfusion bioreactor system 
also needed to be a closed loop system with continuous perfusion, which was accomplished 
with a peristaltic pump. 
 It was important to control the flow rate and pressure through the perfusion bioreactor 
system to ensure the cells did not shear off the scaffold. This could be accomplished by varying 
the size of tubing used, with valves, or with an automated pump. After modeling the system in 
a computer based simulation, we determined the approximate size of tubing necessary to reach 
the optimal flow rate. Then we used the peristaltic pump to further control the flow rate and 
pressure through the system. Additionally, the bioreactor required sterilization between uses to 
ensure a bacteria free environment and no cross contamination between cultures. This could be 
accomplished with autoclaving, ethylene oxide exposure, ultraviolet light, or washing with 
70% isopropyl alcohol. Polyvinyl chloride (PVC) experienced a loss in mechanical properties 
upon exposure to extreme temperatures. To maintain the structural integrity of the bioreactor 
tubing between uses, ethylene oxide (EO) was used to sterilize the device between uses. 
The concept map shown in Fig. 4.1 organized the potential design concepts to achieve 
the in vitro tumor model. Although the problem statement provided encouraged the use of silk, 
different scaffold materials were assessed and compared with the goal being to achieve optimal 
endothelial cell growth and function. 
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Fig. 4.1 Concept map for in vitro endothelialized tumor model. 
 
4.2.2 Preliminary Feasibility Studies 
In the process of seeding the endothelial cells onto the scaffold, there were many 
potential issues that could arise. First, the endothelial cells could not properly adhere to the silk 
scaffold. In this case, it would be necessary to use a Matrigel or collagen coating on the silk 
scaffold to help the endothelial cells adhere to the surface. The endothelial cells could die 
during the seeding process. This would require further investigation into the culture media and 
culture conditions to accurately identify the issue. There were many experienced researchers 
that could help troubleshoot the issue if necessary. 
To make design decisions, 2D cultures were used to determine optimal cell culture 
conditions. From these preliminary subcultures, imaging was used to confirm that the cells 
proliferated to form a confluent monolayer with tight junction formation. These cultures 
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allowed for optimization of fluorescent staining protocols. The staining of the 2D culture 
served as a control for later comparison with the seeded scaffold material.  
When the scaffold was placed into the bioreactor, it was possible that the flow rate 
could be such that it shears the cells off the scaffold. In addition, fluid flow studies were 
conducted to determine the optimal interval post seeding for exposure to flow. The time frame 
identified to maximize cell adhesion ultimately resulted in the highest retention of the 
endothelial layer.  
4.2.3 Design Calculations 
 In order to accurately model in vivo conditions in the bioreactor model, numerical 
calculations were performed to gain an understanding of how fluid flows through capillaries. 
The system was simplified, and flow was modeled as incompressible and laminar. The target 
shear stress value was:  
𝜏 = 2.8 
𝑑𝑦𝑛
𝑐𝑚2
= 0.28 Pa [52].  
The radius (r) of the tubing was set to 5 mm = 0.005 m, which is the size of the existing model.  
 Turbulent flow in blood vessels would be harmful to cells. Therefore, laminar flow was 
assumed, requiring a Reynolds number (Re) ≤ 2300. The viscosity of culture medium was 𝜇 =
0.00078 𝑃𝑎 ⋅ 𝑠 [66]. To simplify these initial calculations, density was assumed to be that of 
water, 𝜌 = 1
𝑔
𝑐𝑚3
, though a more accurate number could be achieved experimentally in the 
future. Using the relation 
𝑉 =
𝜏×𝑟
4𝜇
 , 
the velocity was calculated to be V=0.4487 m/s. This is the maximum velocity of flow required 
through the system. 
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Finally, the maximum flow rate (Q) required was calculated using the diameter (D), 
maximum velocity (V), and the relation  
𝑄 =
𝜋𝐷2𝑉
4
. 
The obtained value was  
3.52 × 10−5
𝑚3
𝑠
= 126.72
𝐿
ℎ𝑟
.  
This is the maximum flow rate required, as it uses the constant diameter and maximum 
velocity. As velocity decreased, so did the flow rate. To confirm the flow was laminar, the 
Reynold’s number was calculated using the formula  
𝑅𝑒 =  
𝜌𝑉𝐿
𝜇
. 
The obtained value from this calculation was 86.219, which confirms that the flow is laminar. 
4.2.4 COMSOL Model as a Computer Based Simulation 
A model of the perfusion bioreactor was completed in COMSOL, a multiphysics 
modeling software, following the example of fluid flow past a cylinder. Parameters calculated 
during the fluid flow analysis were used to create the model seen in Fig. 4.4. These parameters 
included: a mean scaffold inflow velocity of 0.045 m/s, a fluid density of 1000 kg/m3, and a 
dynamic viscosity of 0.00078 Pa-s. The tubing was assumed to have a height of 0.0011 m 
because that was the diameter of the current system, and for preliminary modeling purposes the 
width was set at 0.10 m to hone in on the portion of the tubing containing the scaffold. The 
scaffold height was set at 0.0006 m so it was slightly larger than half of the tube size to ensure 
it would not rotate, and the width was set at 0.0015 m.  
The preliminary model was simplified to depict the fluid flow pattern in a 2D pipe 
system. The model included steady state, incompressible fluid flow to indicate the pattern of 
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the fluid flowing through the pipe and over the scaffold. In the fluid flow model, red indicated 
a larger fluid force while the blue indicated a smaller fluid force. In the velocity model, a larger 
arrow indicated a larger velocity. A COMSOL model was used because it could accurately 
assess and characterize theoretical fluid flow through the system. Modeling the system in 
COMSOL first ensured accuracy when the system was physically made. 
 
 
Fig. 4.2 COMSOL model depicting the flow pattern and velocity around the scaffold in the pipe system of 
the perfusion bioreactor. 
  
The model was then made more complex by translating the geometry into a 3D model, 
depicted in Fig. 4.3. This model depicted the tubing and the scaffold holder of the perfusion 
bioreactor system, but did not include the 3D fluid flow throughout the system. 
 
 
Fig. 4.3 Three-dimensional COMSOL model depicting the tubing and scaffold holder of the bioreactor. 
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4.2.5 Conceptual Designs 
 The team generated conceptual designs utilizing the current functional neuroblastoma 
model as a baseline. This system and the concepts indicated in the concept map were the 
preliminary designs for endothelium and bioreactor systems and are illustrated in the figures 
below. 
 
 
Fig 4.4 Current bioreactor system used in the Coburn lab, including scaffold holder.  
 
 The schematic in Fig. 4.4 represented the system that had been utilized by the lab. A 5 
mL syringe compatible with a syringe pump controlled the unidirectional flow of fluid through 
the silk scaffold into a 50 mL conical tube for media collection. The scaffold was held in place 
utilizing a modified filter system. The filter material was removed and replaced with a silk 
scaffold plug. A PDMS buffer ring sealed the scaffold and device interface which ensured 
media flow through the scaffold material. The system supported neuroblastoma cell growth 
either in the pores of the scaffold or within a Matrigel hydrogel infused in the scaffold. The 
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system favored low flow rates as the media was not recycled through the tissue. The system 
was prone to leaking and formation of air bubbles during media replacement.  
 In order to improve upon the current perfusion bioreactor design, a proposed system 
was developed. This system involved a closed loop with a peristaltic pump and bioreactor to 
hold the scaffold. Plastic tubing was used to construct the system. The system needed to be 
disassemblable, autoclavable, and resealable to prevent contamination. Filtration was not 
necessary. The proposed bioreactor system needed to be able to fit inside a standard size 
incubator to maintain homeostasis during experimentation, and maintain this perfusion for at 
least one week of culture. This system can be visualized below, in Fig. 4.6. 
 
 
Fig. 4.5 Peristaltic pump bioreactor conceptual design.  
 
 The silk scaffold offered adjustable design parameters that allowed for endothelial 
growth in various geometries. For our design we assessed square and cylindrical channels or a 
planar monolayer for endothelial growth and fluid flow. After assessing the logistics and 
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feasibility of potential geometries, we determined that cylindrical channels through the silk 
scaffold would be the most representative of in vivo conditions, but the planar monolayer 
would provide the most feasible model for developing the cell culture process in the narrow 
time-frame. For this reason, we decided to proceed with the planar monolayer scaffold design, 
three examples of which can be seen in Fig. 4.6. Initial fluid dynamics analysis indicated that 
the cross-sectional area would induce turbulent eddies due to the boundary geometry, which 
could potentially vary the shear loading on the cells from that found in vivo. However, initial 
fluid dynamics analysis indicated that the shape of the cross-sectional area would induce 
turbulent eddies due to the boundary geometries that may expose the endothelium to different 
shear stresses than in the body.  
 The second schematic in Fig. 4.6 represents the channel array structure. This geometry 
involved the incorporation of a cell-seeding device and could present difficulty forming the 
endothelium. This geometry would be more representative of capillary bed fluid flow. All 
geometries used required the use of extracellular matrix coating to control the adhesion of 
endothelial cells and future addition of tumor cells. 
  
 
Fig. 4.6 Proposed cell seeding geometries. 
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The ideas presented in the bioreactor design would allow for a continuous perfusion 
loop capable of supporting endothelial tissue. Selection of the planar monolayer seeding 
geometry determined the limiting flow rate and maximum shear loading permitted by the 
engineered endothelium in the bioreactor system. From this initial analysis, the planar seeding 
geometry offered a feasible option with the capability to induce biomechanical loading 
representative of capillary fluid flow in vivo.   
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CHAPTER 5 -- DESIGN VERIFICATION 
 Design verification for the project consisted of three components: verification of the 
silk scaffolds, verification of cell viability, and verification of the perfusion bioreactor. Based 
on literature, it was decided that the silk scaffold must have a stiffness of approximately 10 kPa 
to ensure optimal cell adhesion and growth [7]. In order to obtain this stiffness, multiple 
concentrations of silk scaffolds were tested for their mechanical properties. Cell viability also 
needed to be measured through multiple staining assays. Lastly, it was necessary to perform 
testing on the perfusion bioreactor system to ensure proper functionality. 
 
5.1 Silk Scaffold Mechanical Testing  
Silk scaffolds were fabricated using silk solutions at 3, 6, and 10% silk in a 24 well 
plate. Four scaffolds of each concentration were made and mechanically tested. The top surface 
of the scaffolds were cut down, then a 6 mm biopsy punch was used to cut out a scaffold to 
ensure uniform shape and porosity. Using an LTCM-100 machine with a Chatillon DF force 
gauge (Ametek, Inc.), the compression load in Newtons was measured for each silk scaffold 
using a compression rate of 5.08 mm/min, or 0.0847 mm/sec. Previous experiments have tested 
mechanical properties of silk using a rate of 2 mm/min or 5 mm/min; the rate of 5.08 mm/min 
was chosen because it was the minimum speed the instrument was able to achieve [67-69]. The 
stress on the scaffolds was calculated using the applied force (F), surface area (A), and the 
relation: 
𝜎 =
𝐹
𝐴
 . 
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The surface area was 0.00019 m2 for each of the scaffolds. Strain was calculated as 
vertical displacement of the scaffold divided by the initial displacement. Displacement was 
calculated as distance the load cell moved from its original starting position.  
For each scaffold, three phases were identified in the stress/strain curve. The first phase 
was the linear elastic phase from which the elastic modulus could be determined [68]. The 
second phase was the plastic phase. The transition to the plastic phase was shown by a change 
in slope. The third phase was a stiffening response, characterized by a high increase in stress. 
Using data from the first phase, we were able to create a line of best fit, the slope of which was 
the elastic modulus. The elastic phase for each percentage of silk composition in relation to the 
target stiffness was illustrated in Fig. 5.1. The elastic modulus for each percentage silk 
composition is shown in Table 5.1. 
 
 
Fig. 5.1 Elastic region of stress-strain curve for each percentage of silk composition graphed in relation to 
the target stiffness of 10 kPa. 
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Table 5.1 Elastic modulus for 3%, 6%, and 10% silk scaffolds. 
Scaffold Percent Silk Concentration Elastic Modulus (kPa) 
3% Scaffold 1 0.604 
Scaffold 2 1.06 
Scaffold 3 0.951 
Scaffold 4 1.02 
Average ± SD 0.910 ± 0.2 
6% Scaffold 1 1.27 
Scaffold 2 1.74 
Scaffold 3 1.32 
Scaffold 4 0.975 
Average ± SD 1.33 ± 0.3 
10% Scaffold 1 6.67 
Scaffold 2 8.02 
Scaffold 3 10.1 
Scaffold 4 9.61 
Average ± SD 8.60 ± 1.6 
 
Based on the results obtained and the fact that the desired stiffness of the scaffold was 
10 kPa, it was clear that the 10% scaffold was the closest [7]. Attempts were made to produce 
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scaffolds of higher silk concentrations to achieve a higher stiffness. However, these attempts 
resulted in misshapen scaffolds that could not be removed from the well plates without 
additional damage. For this reason, scaffolds composed of 10% silk were used for the tumor 
model.  
Statistical analysis was also run on the mechanical testing data in the form of an 
ANOVA analysis. The results of the analysis is shown in Table 5.2. The initial results from the 
ANOVA calculated a p-value of 1.279E-06 which indicated that there was statistical difference 
between the three groups of scaffolds.  
 
Table 5.2 Results from ANOVA analysis of mechanical testing data. 
 
However, an ANOVA test only indicated if there was statistical difference between any 
of the groups in the test. To determine if there was statistical difference between all three 
groups or to find out which groups were statistically different from each other, a post hoc test 
was completed in SPSS. The post hoc test that was used was a Bonferroni correction. Results 
from the Bonferroni correction showed that there was statistical significance between the 3 and 
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10% groups and the 6 and 10% groups. However, no statistical significance was found between 
the 3 and 6% groups. Further explanation can be found below in Table 5.3 which contains the 
SPSS output for a Bonferroni correction.  
 
Table 5.3 Results from SPSS Bonferroni correction showing the statistical significance between each group. 
 
5.2 Cell Culture and Viability Testing 
 The viability of the endothelium was validated using a resazurin assay. The resazurin 
dye exhibited weak fluorescent properties but in the presence of cellular respiration byproduct, 
NADH, the dye was reduced and exhibited red fluorescence. An increase in red fluorescence 
indicated the presence of cellular metabolism and confirmed cell viability. Prior to use on the 
silk endothelium monolayers, the resazurin was tested on 2D cultures plated on polystyrene 
plates to confirm assay effectiveness and identify potential toxicity. 
Immunostaining for platelet endothelial adhesion molecule (PECAM1/CD31) and F-
actin were performed to identify the presence of tight junctions and to optimize a method for 
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use in the bioreactor system. The presence of PECAM1 and F-actin in endothelial cells have 
been determined to correspond to tight junction presence and function. These staining 
protocols were optimized on 2D cultures plated on glass cover slips. By comparing antibodies 
and dilutions, the protocol was be optimized prior to implementation on the silk model for use 
in the bioreactor. 
5.2.1 Resazurin Impact on Cell Viability and Proliferation 
 Resazurin was tested for cytotoxicity by testing two time points and determining 
whether the initial exposure impacted cell phenotype and proliferative capacity. The validation 
assay was performed in accordance with the protocol outlined in Appendix B. Fluorescence 
measurements were used to quantify and validate the impact of the assay on cell viability. The 
results were summarized in Fig. 5.2.  
 
 
Fig. 5.2 The effect of resazurin exposure on cell proliferation and viability expressed in fluorescence count 
measurements as represented by the average of four replicates.  
 
 The data presented in Fig. 5.2 confirms the observations that resazurin exposure 
negatively impacts cell proliferation and growth. The red fluorescence count increased between 
Day 3 and Day 5 universally. This effect was observed because the cells proliferated during 
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this culturing period and the overall metabolic activity increased in the wells. However, all the 
wells had exposure to the same conditions, excluding one subset which was exposed to 
resazurin twice. The repeat exposure cells exhibited a lower fluorescence, confirming that 
resazurin exposure hindered the proliferation of the endothelial cells, and suggests that 
repeated exposure should be limited to ensure cell viability. Therefore, for future viability 
testing of cells seeded in the bioreactor, separate samples must be evaluated at each different 
time point, rather than replaced and retested, as repeated exposure to resazurin is not ideal. 
5.2.2 Resazurin Assay to Determine Endothelial Layer on Silk and ECM Viability 
 In fulfillment of the long-term goal to produce a perfusion system to support a 3D 
tumor model with functional endothelium, the system required a scaffold material that had a 
porous structure for support of a 3D tumor model as well as a flat surface to support the 
endothelial monolayer. For this reason we combined the porous, tunable structure of 
lyophilized silk with an ECM hydrogel. We tested the viability of the endothelial cells on 
collagen and Matrigel using a resazurin assay. We plated cells on collagen coated silk, 
Matrigel coated silk, collagen, Matrigel and tissue culture plastic (TCP) surfaces and measured 
fluorescence on Day 3 and Day 7 with no repeat readings. The results of this testing are 
summarized in the Fig. 5.3. It is possible that there was slight machine or reagent variation 
which resulted in a negative viability for Matrigel on Day 7 compared to Day 3, or the cells 
could have initially grown and died prior to the second reading. 
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Fig. 5.3 Resazurin reading on collagen silk, Matrigel silk, collagen, Matrigel and TCP surfaces on Day 3 
and Day 7 in vitro.  
 
 The data in the Fig. 5.3 supports that TIME endothelial cells can proliferate on collagen 
and collagen silk substrates. Although both the collagen silk and collagen surfaces experienced 
less fluorescence than TCP, there were significantly greater readings for these surfaces than 
Matrigel and the baseline. This testing proved that Matrigel did not support adhesion and 
proliferation of endothelial cells. Using this data, we chose to coat the silk scaffolds with 
collagen and we seeded the cells 3 to 4 days prior to exposure to dynamic culture. This period 
accounted for the relatively little proliferation over baseline in the first few days. This gave the 
cells time to adhere to the ECM material before inducing shear force on the culture.  
5.2.3 CD31 Immunostaining for Endothelial Tight Junction Formation 
 Platelet endothelial cell adhesion molecule (PECAM 1), also known as CD31, was 
selected as the target for immunostaining for endothelial cell function for its role in the 
regulation of endothelial barrier function through an uncharacterized mechanism. Cells were 
cultured on glass coverslips until reaching confluency. The cells were fixed and stained with 
CD31 primary antibody and Alexa-Fluor conjugated secondary antibody. Our selected 
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antibodies were tested in parallel to an optimized protocol to characterize efficiency and 
evaluate the protocol that was used for validation of the endothelial function of the 
endothelialized scaffold.  
 Both primary antibodies selected for this optimization procedure targeted 
CD31/PECAM1 but were acquired by different vendors. The goal of the study was to compare 
the available antibody to the published protocol to determine the effectiveness of the cost 
effective antibody to the published one. In addition, the testing was performed to determine 
what aspects of the protocol need to be modified to achieve the desired result. The images in 
Fig. 5.4 utilized the first set of antibodies developed from the protocol used in the Rolle 
laboratory (WPI, Worcester MA). Appendix C Part A details the antibodies and dilution factors 
for this protocol. The comparison protocol was developed from the Page laboratory (WPI, 
Worcester MA) and the relevant product numbers and dilutions can be found in Appendix C 
Part B.  
 The images in Fig. 5.4 represent the control set for the staining optimization. For the 
preliminary study, the primary and secondary controls for both protocols were tested to 
determine target affinity of the selected antibodies.  
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Fig. 5.4 A) Primary antibody control for the protocol in Appendix C Part A using TIME endothelial cells 
Day 7 in vitro with Hoechst (blue) and CD31 (red). B) Primary antibody control for the protocol in 
Appendix C Part B using TIME endothelial cells Day 7 in vitro with Hoechst (blue) and CD31 (red).  
 
 The nuclear stain confirmed the presence of endothelial cells in the staining as indicated by the 
presence of blue. These images did not exhibit red fluorescence over background .as expected due to 
the lack of red staining and resulting absence of the proper fluorescent probe.  
 
 
Fig. 5.5 Alexa-Fluor 568 goat anti-rabbit secondary antibody (red) control for staining protocol outlined in 
Appendix C Part A and Appendix C Part B using TIME endothelial cells Day 7 in vitro. 
  
The images in Fig. 5.5 were the secondary controls for the optimization testing. The 
minimal red fluorescence was indicative of background and confirmed that there was no 
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affinity of the antibody that predisposed the images to bias. The images confirmed that the 
fluorescence detected on the images results from the CD31 antibody. 
 
 
Fig. 5.6 Immunostaining of TIME endothelial cells Day 7 in vitro with Hoechst (blue), phalloidin (green) 
and CD31 (red) using protocol from Appendix C Part A. 
  
In Fig. 5.6, the Hoechst nuclear/DNA stain and phalloidin cytoskeletal stain confirmed 
the presence and morphology of cells on the slide. The alignment of the blue nuclei within the 
green cytoskeletons suggested a consistent cell morphology and growth characteristics. The 
expression of CD31 exhibited weak red fluorescence due to its relatively low concentration 
compared to nucleic acids and F-actin. 
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Fig. 5.7 Immunostaining of TIME endothelial cells Day 7 in vitro with Hoechst (blue), phalloidin (green) 
and CD31 (red) for Appendix C Part B protocol. 
 
 Fig. 5.7 for the second primary antibody expressed a brighter red fluorescence than the 
previous antibody. The red patches in the image appeared in areas with confluent nuclei. This 
suggested that CD31 expression occurred in areas of cellular contact. The results of this 
imaging supported the use of our selected antibody as it provided better cell visibility at a 
lower cost than the optimized protocol.  
 The staining pictured in Fig. 5.8 was performed to further test the potential to use 
CD31/PECAM1 antibody to test the functionality of the endothelial monolayer. To increase 
red fluorescence, the coverslip surface area was increased to 4 mm2 and the cell seeding 
number was increased to promote a confluent monolayer. These changes were intended to 
allow more space for a confluent monolayer to grow, providing more cells to be stained and 
observed. Increased confluency resulted in more cellular contact providing more surface area 
for tight junction formation. Despite the increased cell density, the CD31 fluorescence 
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remained indistinguishable from background. The images from the repeat staining are 
illustrated in Fig. 5.8.  
 
 
Fig. 5.8 Immunostaining of TIME endothelial cells in vitro with Hoechst (blue), phalloidin (green) and 
CD31 (red) using optimized Appendix C Part B protocol. 
 
Despite the increased confluency, the CD31 was still indistinguishable over 
background. However, this imaging revealed that the phalloidin was not only present, but also 
spatially organized around nuclei at the cell perimeter. Phalloidin staining targeted the F-actin 
component of the cytoskeleton. F-actin was found in both cortical actin surrounding 
endothelial cells and in stress fibers that facilitate endothelial tight junction formation. Fig. 5.8 
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indicated that these structures were more prevalent when visualized using immunostaining. In 
addition, the spatial orientation and distribution of the phalloidin supported the presence of 
cortical actin. Because F-actin played an essential role in barrier stabilization and stress fiber 
formation, it was used to determine endothelial tight junction formation [70].  
 
5.3 Verification of Perfusion Bioreactor System 
5.3.1 COMSOL Verification for Fluid Flow 
 A COMSOL model was used to model the shear forces on the endothelial cell 
monolayer due to increased fluid velocity through the bioreactor. Fig. 5.9 illustrates the fluid 
flow through the perfusion bioreactor with an inlet velocity of 0.100 m/s. With the fluid flow 
from left to right, this model proved that there was a high fluid force near the inlet end of the 
scaffold holder. The force on the upper left corner of the scaffold caused shearing of the cells 
on this part of the scaffold, which was detrimental to the model. Using this computer model of 
the perfusion bioreactor system was the first step to verifying the correct calculated fluid flow 
rate through the bioreactor. 
 
 
Fig. 5.9 COMSOL model illustrating an increased fluid force around the scaffold with an increased inlet 
velocity. 
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5.3.2 Initial Bioreactor Setup 
 An initial bioreactor setup was created using a Watson Marlow 323 series peristaltic 
pump. Tubing with an inner diameter (ID) of 1/16 inch was run through the first channel on the 
pump rollers. One end of the tubing was pulled through a 3-mm hole that had been biopsy 
punched through the septum cap of a vial of water. The other end of the tubing was connected 
to 3/16 inch ID tubing via polypropylene McMaster-Carr fittings. This 3/16 inch ID tubing was 
connected to a Millipore Swinnex with the filter removed. The Swinnex later functioned as a 
holder for the scaffold but remained empty for testing. The other end of the Swinnex filter was 
connected to more 3/16 inch ID tubing, which was connected to 1/16 inch ID tubing and 
inserted through an additional 3mm hole in the septum cap. A 50-mL syringe attached to a 
syringe filter was pressed through a third hole in the septum cap to pressurize the liquid. A 
picture of the current bioreactor setup can be found in Fig. 5.10. 
 
 
Fig. 5.10 Initial bioreactor testing with blue food coloring. 
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 Using a syringe attached to a 1/16” ID fitting, water was pushed through one end of the 
tubing until all of the tubing was full. The septum cap was screwed tightly to the vial of water 
and the syringe, at right in Fig. 5.10, was depressed to pressurize the system. The peristaltic 
pump was then turned on and started at 100 rpm. A small amount of water leaked through the 
Swinnex so it was tightened to stop the leak. Tubing was being pulled into the pump so the trial 
was ended.  
 For a second trial, stoppers were added to the outside of the tubing that was run through 
the pump. In addition, blue food coloring was added to the water in the vial so that water could 
be visualized as it moved from the vial through the tubing. For this trial the pump was turned 
down to 60 rpm to assist with visualization. Blue water flowed from one end of the tubing to 
the other, until all the water in the tubing was blue. There were no leaks in the tubing and all 
the tubing remained in place.  
5.3.3 Bioreactor Fluid Flow 
To determine fluid flow through the bioreactor system, the system was set up on the lab 
bench as demonstrated in Fig. 5.10. The return tubing was removed from the media reservoir 
and placed in a graduated cylinder to measure volumetric output of our system. The flow rate 
was calculated with the measured output volume of water from the tubing in 30 second 
periods. This process was repeated for three different pump settings to correlate pump rpm and 
flow rate through the system. The results from these trials are summarized in Table 5.4.  
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Table 5.4 Bioreactor volumetric flow rate measurements. 
Perfusion Pump Rate 40 rpm 60 rpm 100 rpm 
Trial 1 Output Volume (mL) 7.0 11.0 17.0 
Trial 2 Output Volume (mL) 7.5 10.0 17.0 
Trial 3 Output Volume (mL) 7.0 10.5 17.0 
Average Output (mL) 7.2 ± 0.3 10.5 ± 0.5 17 ± 0.0 
Flow Rate (mL/s) 0.2 0.4 0.6 
 
5.3.4 Bioreactor Fluid Dynamics Analysis 
 Using the data collected from the volumetric flow rates above the velocity and pressure 
drop along each tubing segment was calculated. The Hagen-Poiseuille Equation was applied to 
calculate the pressure change across the tubing. A spreadsheet was tabulated to back solve for 
pressure and fluid flow velocity in the scaffold holder. Fig 5.11 outlines the variables and 
conditions for each segment.  
 
Fig. 5.11 Schematic of tubing order and dimensions used for fluid dynamics calculations. 
 
 Using the output volumetric flow rate and operating under the assumption that vascular 
endothelial growth media possesses the same density as water, the following mass flow rates 
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and fluid velocities were calculated for the three settings of the peristaltic pumps. The viscosity 
of cell media was assumed to be 0.94 cP [71]. The law of conservation of mass was applied to 
ensure that the mass flow rate in each segment was held constant. This ensured that the mass 
flow rate exiting the system was the same going through the scaffold holder. Using this 
variable, the velocity calculation was performed. These values were reported in Table 5.5 for 
each peristaltic pump setting.  
 
Table 5.5 Mass flow rates and fluid velocity for 40 rpm, 60 rpm and 100 rpm peristaltic pump settings. 
Peristaltic Pump 
Speed (rpm) 
Mass Flow 
Rate(10-4 kg/s)  
Fluid Velocity 
(10-4m/s) 
40 2.3 0.5 
60 3.5 0.8 
100 5.6 1.2 
 
5.3.5 SolidWorks Fluid Simulation and Wall Shear Stress Calculation 
 A simple SolidWorks model was generated to mimic the dimensions of the channel 
between the silk scaffold and boundaries of the Swinnex scaffold holder. The part modelled 
was a half circle cross-sectional channel that possessed the diameter and length of the Swinnex. 
SolidWorks Fluid Simulation function was utilized to analyze wall shear stress induced by the 
complex channel geometry. The calculations were primarily focused on the planar surface 
shear stress to determine what stress would be applied to the cell monolayer in the bioreactor.  
 The simulation required establishment of channel boundary conditions, inlet velocity 
and pressure conditions. Using these values, the system was able to model fluid flow through 
the part and output average wall shear stress and a heat map detailing stress at a particular 
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location. The average wall shear stresses for each peristaltic pump setting and flow rate are 
detailed in Table 5.6.  
 
Table 5.6 Average wall shear stress and volumetric flow rates in the scaffold holder for 40 rpm, 60 rpm and 
100 rpm peristaltic pump settings. 
 
Peristaltic Pump 
Speed (rpm) 
Volumetric Flow 
Rate (mL/s) 
Average Wall Shear 
Stress (Pa) 
40 0.2  0.01 
60 0.4  0.02 
100 0.6 0.03 
 
Based on the results we determined that the system has the capability to support low 
flow rates representative of early angiogenic states. When hollow blood vessel formation 
begins and branching occurs, blood flow rate is lower to prepare the vasculature for exposure 
to higher flow rates. Once cells withstand dynamic loading, we can increase the flow rate and 
thus wall shear stress to increase biomechanical loading of the cells to induce phenotypic 
changes seen in natural blood vessel tissue. The initial runs were performed at a flow rate of 
0.4 mL/s to test the ability to maintain static culture. The shear stress distribution over the 
scaffold surface is modeled in Fig. 5.12. 
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Fig. 5.12 Heat map of scaffold surface detailing distribution and magnitude of wall shear stress in the 
Swinnex scaffold holder at a volumetric flow rate of 0.4 mL/s. 
 
 The green area of the heat map indicated the highest concentration of wall shear stress. 
This area corresponds with the inlet location where the scaffold is supplied with media. For 
this reason, the scaffold needed to be set back in order to avoid shearing of the endothelial 
monolayer at the inlet.  
 The embedded silk scaffold cell seeding surface was constrained due to the 
lyophilization inefficiencies with high volume silk solutions. The computational fluid modeling 
was altered to reflect the modified geometry of the scaffold which consisted of a 4 mm x 8 mm 
planar surface for endothelial adhesion and growth. The SolidWorks half-moon channel model 
was modified to calculate wall shear stress on the decreased length scaffold as depicted in the 
heat maps generated below. The first bioreactor trial was run at 60 rpm with a flow rate of 0.4 
mL/s. The shear stress distribution on the cell surface of the scaffold is depicted in Fig. 5.13.  
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Fig. 5.13 Heat map of scaffold surface detailing distribution and magnitude of wall shear stress in the 
Swinnex scaffold holder at a volumetric flow rate of 0.4 mL/s for the modified silk scaffold geometry.  
 
 The model indicates that most of the scaffold is above the blue, or low, shear stress 
level. Most of the scaffold surface lies in the range of 0.02 Pa which is about an order of 
magnitude below what literature reports for physiologically relevant shear stresses. However, 
the short scaffold surface does not allow for steady state to occur over the cell surface. As a 
result, there is an uneven distribution of shear stresses throughout the scaffold length, which 
may contribute to either the shearing of the seeded endothelium or collagen layer. In light of 
these potentially damaging effects, we modeled the system at a setting of 10 rpm on the 
perfusion pump, which corresponds to a volumetric flow rate of 0.069 mL/s. This system 
models flow rates that are significantly lower than physiological conditions. These flow rates 
have been observed to promote endothelial spreading and increase protein expression that 
strengthens adhesions complexes and adhesion and primes the cell monolayer for higher shear 
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stresses. Fig. 5.14 illustrates the changes in shear stresses attributed to the alteration of flow 
rate. 
.  
Fig. 5.14 Heat map of scaffold surface detailing distribution and magnitude of wall shear stress in the 
Swinnex scaffold holder at a volumetric flow rate of 0.07 mL/s for the modified silk scaffold geometry.  
 
 The surface mesh heat map generated for a flow rate of 0.07 mL/s demonstrates the 
steady state flow achieved over the surface. The entire scaffold possessed uniform shear stress 
distribution falling under the category of extremely low flow rate. The benefit of operating the 
system at this flow rate provided a twofold approach to ensure cell viability and adhesion, as 
well as attempting to precondition the cells to withstand higher flow rates in the future. This 
computational modeling aided in the optimization of flow rates to prevent cell shearing and 
maintain endothelial adhesion.  
5.3.6 Resazurin Fluorescence Intensity after 7 Days for Static and Dynamic Cultures 
 Silk scaffolds were seeded at 100,000 cells per scaffold and were cultured for a 
duration of three days prior to placement in the perfusion bioreactor. Resazurin fluorescence 
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intensity was measured following this three-day adhesion period (considered Day 0 for the 
dynamic studies) to ensure the presence of viable cells prior to exposure to the dynamic 
conditions of the bioreactor. After an additional seven days of culture inside the bioreactor, 
these dynamic scaffolds were exposed to resazurin to assess cell viability compared to 
background and silk-only controls. The results of these assays can be seen in Fig. 5.15. Due 
scaffold availability we were only able to run one sample for each condition which did not 
permit the use of statistics for this trial.  
 
Fig. 5.15 Fluorescence intensity readings for Day 0 and Day 7 for static and dynamic culture conditions. 
 
 The data in Fig. 5.15 demonstrated that fluorescence intensity increased between Day 0 
and Day 7 static conditions which correlates to cell proliferation. This data indicated that 
endothelial cells were viable on the collagen embedded silk scaffolds. The data indicated a 
decrease fluorescent intensity for the dynamic culture in the bioreactor. Although there was a 
drastic decrease, there was still a low reading which proved the existence of viable cells. This 
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data supported the need for modeling of early angiogenic flow environments. The low 
fluorescent intensity suggested the cells sheared due to flow rate. This observation resulted in 
the modification to lower the media flow rate within the bioreactor system.  
5.3.7 Confocal Microscopy Tight Junction Verification  
 
Fig. 5.16 Confocal image of statically cultured endothelial cell monolayer at 10X with Hoechst nuclear stain 
(blue) and phalloidin extracellular matrix stain (green). 
 
 Confocal microscopy of the static culture at Day 7, as seen in Fig. 5.16, indicated that 
cells formed a confluent monolayer on the collagen embedded-scaffold. The nuclei appeared to 
be centralized to one plane thus indicating that the monolayer formed on top of the scaffold 
and did not significantly infiltrate the porous silk scaffold. This localization of cells to the top 
layer supports the use of these scaffolds for future tumor cell co-culture. 
 ImageJ was used to quantify the spreading of the cells by setting a scale, measuring the 
lengths, and averaging the values. The average length for the statically cultured cells was 39.0 
μm and the average length for the dynamically cultured cells was 50.2 μm. These results 
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supported our expectation that dynamic loading would induce shear stresses that would result 
in the elongation of the endothelial cells. This indicates that the cells would be more effectively 
pre-conditioned for higher flow rates in the future. 
5.3.8 Analysis and Comparison of the Static and Dynamic Collagen-Embedded Scaffolds 
 Hoechst, phalloidin and AdipoRed stained the nuclei, extracellular matrix and scaffold 
counterstaining, respectively. The fluorescent images demonstrate the morphology and 
orientation of the endothelial cell layer. Fig. 5.17 displays the immunostained silk scaffolds for 
both static and dynamic culture conditions.  
 
 
Fig. 5.17 10X Confocal microscopy images for static endothelial culture (left) and bioreactor endothelial 
culture (right) with Hoechst nuclear stain (blue), phalloidin extracellular matrix stain (green) and 
AdipoRed (silk) stain.  
 
 The images above effectively verify that the cell seeding method ensures endothelial 
cell adhesion following 7 days in vitro. Since neither image shows AdipoRed fluorescence, it 
indicated that the cells reside on the surface of the collagen-embedded silk scaffold.  
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 Using ImageJ, it was calculated that the cells on the static scaffold cover a total area of 
2.4 x 106 μm2 and 1.8 x 106 μm2 on the dynamic scaffold. This is 99% and 73% scaffold 
coverage with cells for static and dynamic culture, respectively. The cells grew into a more 
confluent monolayer in static culture than in dynamic. 
5.3.9 Sterility and Biocompatibility of Bioreactor  
 A singular bioreactor apparatus, devoid of scaffold and cells, was run in parallel to a 
dynamic culture study. Media was added to the system and sustained in the bioreactor for a 
total of 7 days. This media was collected in a sterile manner after the trial. A 6-well plate 
seeded at 30,000 cells per well was plated with vascular endothelial growth medium. At the 
first media change, fresh vascular endothelial growth medium was added to half of the wells of 
a 6-well plate and the collected bioreactor medium was added the remaining wells. The cells 
were cultured for one week without media change in order to observe any bioreactor toxicity 
and to confirm the sterility of the bioreactor culture system. The cells were observed for signs 
of contamination or toxicity and imaged on Day 3 to observe cell morphology and 
proliferation. 
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Fig. 5.18 A) 10X brightfield image prior to first media change.  B) 10X brightfield image on Day 3 after 
media exposure for collected bioreactor medium. C) 10X brightfield image on Day 3 after media exposure 
for regular vascular endothelial growth medium. 
  
The images in Fig. 5.18 demonstrated that cells in both culture conditions proliferated 
within the first three days of exposure. The ability of the cells to replicate indicated that the 
bioreactor did not release toxins that are potentially lethal to the cells. The media also showed 
no sign of contamination as the media was transparent and there were no signs of 
contamination in the images. These images confirmed that the reactor sustains sterile culture 
and did not have negative degradation products that would kill the cells.  
 A resazurin assay was performed following 7 days of cultivation without changing the 
respective medium. This assay quantifies cellular viability of so that the cell viability for each 
condition can be compared. Fig. 5.19 indicates that there is less than a 7% change fluorescence 
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intensity between the cultures in the regular vascular growth medium and bioreactor medium 
respectively.  
 
Fig. 5.19 Resazurin fluorescence for bioreactor and regular vascular growth medium after 7 days of 
exposure normalized to baseline readings. 
 
The data confirmed that the media from the bioreactor did not induce cytotoxic effects 
on the cells. This lack of cytotoxicity indicated that no harmful byproducts were being released 
into the media via the tubing or scaffold material. In addition, the transparency of the media 
throughout the trial proved the system was closed and sterile. Initially, we determined that we 
wanted the bioreactor media to result in resazurin conversion that was within 10% of the 
untreated control cells. Previous analysis of baseline readings indicated that our plate readings 
result in an intra experimental variability of ±9.9%. This experimental variance was calculated 
based on the baseline readings of two replicate silk viability resazurin assays. The two 
experimental trials were designed with the same controls and same volume of reagent. 
Therefore, the reading of the resazurin baseline determines the variance of fluorescence 
intensity between trials. The media collected from the perfusion bioreactor system was 6.5% of 
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the regular vascular endothelial growth medium. This performance was a singular trial that 
could not be analyzed with statistical analysis but with repeat trials would be assumed to yield 
a p-value indicative of no statistical significance. The 6.5% deviation from the regular vascular 
growth medium falls below the minimum tolerance threshold and therefore indicates that the 
bioreactor system is not cytotoxic.  
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CHAPTER 6 -- FINAL DESIGN AND VALIDATION 
6.1 Final Design 
 The final design of the project used the perfusion pump to recirculate media through 
tubing and over the 10% silk scaffold that incorporated an endothelial cell monolayer. In order 
to do this, the perfusion pump was first set up according to manufacturer’s instructions. The 
tubing had been sterilized using ethylene oxide, and was opened inside of the hood and 
attached to ensure sterility. The half-moon scaffold was inserted into the PDMS ring, which 
was then inserted into the Swinnex as seen in Fig. 6.1.  
 
 
Fig. 6.1 10% silk scaffold cut to a half moon with endothelial cells seeded on it. The scaffold is inserted into 
the 2 mm thick PDMS ring, which is then inserted into the Swinnex. 
 
As seen in Fig. 6.2 A), the ends of the tubing were pulled through holes in the septum 
cap, which had been previously made with a 3-mm biopsy punch. Fifteen mL of cell culture 
media was pipetted into the vial and the septum cap was screwed on to complete the closed 
loop of tubing. Fig. 6.2 B) illustrates this. One end of the tubing extends deep into the media 
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reservoir; this is the inlet. As the media is pumped through the tubing, it returned to the vial, 
dripping media from above so it did not add any air bubbles into the media reservoir.  
 
 
Fig. 6.2 A) Tubing being pulled through the 3 mm holes that were biopsy punched in the septum cap of the 
media vial. B) Media vial filled with media showing how the tubing sits in the vial. 
  
The third hole in the septum cap was fitted for the air filter, which was screwed on to a 
60-mL syringe filled with 5% CO2 air from the incubator. The syringe was depressed, which 
caused the system to become pressurized and allowed media to slowly flood the tubing system. 
Tape was used to keep the plunger of the syringe depressed and the system pressurized, which 
can be seen in Fig. 6.3. Finally, the closed system was moved out of the incubator and hooked 
up to the perfusion pump, which can be seen in Fig. 6.4. The media vial and Swinnex were set 
in the incubator, and binder clips were used to ensure the tubing would not crimp in the 
incubator door. Fig. 6.5 shows which parts of the perfusion bioreactor were in the incubator 
and which were not. 
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Fig. 6.3 Media vial with air filter and 60 mL syringe connected. This image illustrates how the tape was 
used to ensure constant pressure in the system. 
 
 
Fig. 6.4 Setup of the bioreactor outside of the incubator showing the perfusion pump and closed loop 
system of tubing and media. 
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Fig. 6.5 Setup of the bioreactor inside of the incubator showing the perfusion pump and closed loop system 
of tubing and media. 
 
6.2 Industry Standards 
Industry standards considered for the development of the project design were outlined 
in Section 3.3. Most of the considered standards were incorporated into the initial design. Silk 
was extracted according to protocol then scaffolds were lyophilized according to the standards 
set forth by the International Society of Lyophilizing and the FDA for pressure gauge 
measurements, cycle time and machine maintenance. Cell culture was performed according to 
ISO standards 24998:2008 and 20391-1 and the ATCC Time Cell subculture protocol. The 
bioreactor system was sterilized according to ISO standards for general sterilization, moist heat 
sterilization, and ethylene oxide sterilization. For future work, ISO standard 13485 for medical 
devices should be followed.  
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6.3 Project Impact 
 When performing research, designing, and testing our device, it was imperative that we 
considered how each could affect economics, the environment, and society, and the types of 
impacts the bioreactor device could have in the realm of health and safety. We also 
investigated the manufacturability and sustainability of our device to ensure that it was 
effective and offered practical potential for investigative applications.   
6.3.1 Economics  
 A cheaper, more accurate in vitro tumor model would decrease pharmaceutical research 
and development spending. The low-cost materials of this bioreactor would decrease the need 
for spending on excess animal studies. The creation of human hierarchical endothelium 
structure would provide results that more accurately represent those of human clinical study so 
as to reduce animal usage and the number of preclinical assays required during compound 
discovery. Overall, our tumor model would increase the revenue of pharmaceutical companies 
by reducing the costs associated with cancer modeling and failed human trials. There would 
also be a reduction in the cost to patients. With more accurate and targeted drugs, patients 
would be able to spend less money and time on treatments. 
 Our tumor model would also help to reduce the money spent on animal research. By 
producing an in vitro tumor model that accurately mimics the environment in vivo, there would 
no longer be as great a need to perform tumor model studies using animals. This would impact 
the current market for in vivo animal models and cause a decline in this industry.  
Lastly, the tumor model we developed would help to reduce media and serum waste. 
The ability to re-perfuse media will reduce the amount that is required for each study. Also, the 
media required to allow for reperfusion though our small-scale tumor model will be minimal. 
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This would significantly reduce the cost of in vitro studies and also impact the sales of 
companies that market media and serum.  
6.3.2 Environmental Impact  
 This bioreactor and tumor model posed little threat to the environment but could 
potential induce effects through its use and implementation. The main attraction to this system 
is that it was able to be disassembled, sterilized, and reused. This greatly reduced the amount of 
waste that is created when performing in vitro studies. Materials were re-used as much as 
possible, and those that required disposal were done so appropriately in biohazardous waste 
where they were disposed of in accordance with university regulations. Non-hazardous paper 
waste was recycled as much as possible. Additionally, through the use of a multi-channel 
peristaltic pump, multiple trials were completed simultaneously, thus reducing energy 
consumption by keeping the setup limited to one pump. The pump, tubing, and media reservoir 
were designed to fit inside a standard-size incubator, the temperature was controlled this way, 
rather than using more energy to attempt to regulate the conditions of an entire room. Because 
this setup was reusable, it resulted in less waste than traditional cell culture methods that utilize 
multiple well plates, tips, dishes, and flasks. 
 The reperfusible and recyclable nature of this system also prevented the excessive use 
of media and other reagents. While this was first and foremost a cost-efficiency issue, it also 
reduced the excessive waste of growth factors, proteins or serum present in the cell medium. 
Additionally, the self-contained media reservoir prevented leakage into the environment and 
ensured that all biological waste can be disposed of properly. 
 Since the bioreactor utilized potentially toxic ethylene oxide sterilization, 
environmental effects were considered. This method was widely used for devices which are 
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sensitive to dry heat and/or steam. It was imperative that the sterilization processes be well 
controlled, well documented, and performed on frequently-inspected equipment to ensure that 
it was not malfunctioning. Such errors could cause negative environmental pollution effects 
[72].  
6.3.3 Societal Influence  
 This tumor model would have a large impact on society due to its improved ability to 
cheaply and accurately test cancer treatments. By using this more accurate in vitro model, 
pharmaceutical companies can create improved cancer treatments at a lower cost, making a 
more effective cancer treatment available to patients. This would improve patient outcomes 
and increase life expectancy. In addition, improved treatments may not have some of the 
detrimental side effects present with current treatments, improving societal productivity of 
patients undergoing treatment.  
6.3.4 Political Ramifications  
 The use of this in vitro tumor model could create a more consistent global approach to 
cancer research, which could increase efficiency and output of cancer treatments. By enabling 
research in all regions of the world, more specific genetic factors contributing to cancer in a 
region can be identified. Additionally, reducing the cost of cancer treatments could increase 
global availability.  
6.3.5 Ethical Concerns  
 By developing an accurate in vitro tumor model, there will be less need for animal 
tumor models. Currently, animal models provide a more accurate tumor model when compared 
to in vitro because in vivo models can exhibit accurate endothelialization of the tumor. This in 
vitro model incorporated a perfusion bioreactor, which more accurately mimicked the tumor 
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microenvironment and provided a more accurate monolayer of endothelial cells. This accuracy 
provided a more efficient in vitro model, reducing the need for animal models. 
 Additionally, this tumor model allowed for specific sourcing of the cells, meaning that 
cancer patients could potentially be able to create a personalized tumor model with their own 
cancer cells. Using a patient’s own cancer cells to create an in vitro model would allow for 
more personalized, and perhaps more effective cancer treatment. However, this could be time 
consuming and expensive to implement. 
6.3.6 Health and Safety Issues  
 An in vitro tumor model such as this one could help to improve the health of patients 
with cancer by providing them with more accurate and effective treatment. This tumor model 
can be cocultured with an individual patient’s cancer cells, on which different cancer therapies 
can be tested. After finding the most effective treatment for each individual, the treatment can 
then be applied to the patient. This will reduce the need for ineffective, “trial-and-error” cancer 
treatments, while also reducing undue pain and suffering of the patient.  
 Additionally, this type of in vitro model will benefit researchers as well. Because this 
model is developed inside of a closed loop perfusion system, it offered minimal exposure of 
biological hazards to the researcher. This reduced any potential exposures to biological hazards 
and possible infections that may result from exposure. 
6.3.7 Manufacturability  
 The bioreactor system and endothelial scaffold system provided a low cost option for 
the study of tumor vasculature. The system itself consisted of standard 1/16” rubber tubing 
which can be purchased in large quantities and cut to whatever size accommodates the 
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intended location of the system. The tubing segments were connected by standard sized 
McMaster Carr tube fittings that can be purchased at the size of the tubing in our system.  
The bioreactor ensured adequate temperature control through compatibility with 
standard incubation systems. By using existing equipment, the system can be universally 
adapted to tissue culture laboratories without additional expense for a CO2 or temperature 
regulated system.  
 The silk material offered a low-cost scaffold with robust and tunable mechanical 
properties. Following harvest and silk processing the silk was dissolved in an aqueous solution. 
Using dialysis membranes and Millipore water the silk was effectively concentrated to a 
desired percent silk concentration. This control was achieved through variation of the volume 
of water that was added to the silk solution. The aqueous solution was dispensed into molds or 
well plates to achieve scaffolds of a specific size or structure. Well plates were used to 
repeatedly produce uniform scaffolds in high quantities. Standard size biopsy punches and 
razor blades were used to create a half moon scaffold a flat surface area for cell seeding. These 
scaffolds were autoclaved by the current system utilized by the laboratory. The dimensions and 
shape of the silk scaffolds produced can be altered to produce silk with varying thicknesses and 
geometries to best suit the needs of the bioreactor set up. If the system is adapted for 
widespread use in academic and pharmaceutical settings the silk could be mass produced, sold 
and distributed by a location with access to a lyophilization system. Otherwise the lab must 
have access to a lyophilizer to create a porous structure to allow for future coculture 
capabilities with neuroblastoma tumor cells. Collagen can be obtained easily through the 
current lab distributor and the cost for system operation should be low due to the fact that only 
a small volume is required to saturate the scaffold to provide a smooth surface for endothelial 
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attachment and proliferation. Additionally, the capacity of the bioreactor system will be limited 
by the number of slots available on the peristaltic pump. A larger pump would be required for 
large scale industry requirements.  
6.3.8 Sustainability  
 The production of our bioreactor system presents a sustainable option to conserve 
materials and drive fluid through our system. The system operated on a low output peristaltic 
pump. Additionally, the bioreactor was stored in a standard incubator. Because of this design 
constraint, the bioreactor itself was a low power output device.  
 One goal of the perfusion media system was to conserve media to avoid wasting serum 
and other growth factors. As a result of continuous loop perfusion, there was a decrease in 
media consumption which conserved biological waste products. The system consisted of 
commonly used lab equipment which highlighted the universal opportunities for application of 
the bioreactor system. The system was sterilized via ethylene oxide which although sterilizes 
the materials presents the opportunity to reuse and recycle items from previous trials. 
Therefore, the system would require a certain amount of tubing sets that corresponds to the 
maximum number of tubing clamps. The use of a perfusion pump allowed for simultaneous 
runs which reduced the time required for each study while also scaling up the culture 
conditions. This conserved product consumption and maximized efficiency of data collections 
from the system.  
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CHAPTER 7 -- DISCUSSION 
 One of the major limitations with in vitro tumor models currently being used in 
industry is that they do not account for accurate endothelialization of the model. While there 
are other drawbacks to in vitro models, this project focused solely on the endothelialization of 
a tumor model. This project successfully created a method to dynamically culture endothelial 
cells in a monolayer on a silk scaffold, resulting in a more physiologically accurate in vitro 
tumor model. At the conclusion of the project endothelial monolayers could be fabricated due 
to an optimized cell seeding method. These scaffolds could be maintained in a sterile, 
cytocompatible perfusion bioreactor system for a duration of one week. The bioreactor system 
was adjusted to prevent cell shearing but requires further optimization to result in a uniform 
endothelial distribution on the scaffold surface.  
 
7.1 Design of a Method for Scaffold Endothelialization 
 Collagen embedded, lyophilized silk scaffolds were used to culture cells both statically 
and dynamically. The collagen was used to promote better adhesion of the cells to the silk 
scaffold and a contiguous layer for culturing. Each bioreactor trial contained a test set of Day 0 
scaffolds that were used to gauge the effectiveness of the cell seeding protocol prior to 
exposure to the bioreactor. The presence of fluorescence intensity over the baseline reading 
indicates the presence of viable cells on the scaffold. This data supported the ability of the 
endothelial cells to adhere to the collagen-silk surface.  
 After the completion of a bioreactor experiment, the silk scaffolds were fixed and 
stained to assess endothelial distribution across the scaffold. In addition, the use of confocal 
microscopy gave us the ability analyze the 3D distribution of the endothelium. The images that 
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contained cells did not stain positively for AdipoRed indicating that there was no silk in that 
plane where the endothelial cells resided. The absence of silk indicates that the endothelial 
cells successfully adhered to the collagen coating rather than the silk. This formation of a 
hierarchical distribution permits future tumor cell infiltration in the porous scaffold region. In 
addition, the images stained positively for f-actin. The production of this extracellular matrix 
indicates the presence of essential binding sites for tight junctional proteins. The formation of 
extracellular matrix also contributes to the cell adhesion to the collagen coating. This increased 
adhesion helps to ensure cell layer integrity when exposed to dynamic loading.  
For the assessment of confluency, the static scaffolds were maintained and fixed in 
parallel with the dynamic cell systems. The capturing of these images provided spatial data 
regarding percentage of surface coverage. Static cultures formed a nearly uniform monolayer 
and exhibited a surface cell coverage of 99% in the most confluent regions. The dynamic 
scaffold reached a coverage rate of 72%. The confluency of the static cultures indicated that 
the seeding method for attachment of TIME endothelial cells to the collagen surface coating 
was effective.    
 The combination of resazurin viability outputs, extracellular matrix formation and 
cellular distribution indicated that the cell seeding method could produce an endothelial layer 
that is viable and confluent in static conditions. Additionally, the bioreactor was able to 
produce an endothelial layer but with more gaps throughout the scaffold surface. This 
difference in distribution most likely stems from early cell shearing from the exposure to media 
flow. Due to the early incidence of shearing, dynamic cultures may benefit from a culture 
duration of more than one week to allow for regrowth and to achieve a similar level of 
confluence as the static cultures.  
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7.2 Characterization of Perfusion Bioreactor System for Dynamic Culture 
 Testing of the perfusion bioreactor system began with a flow rate of 60 rpm to try to 
mimic in vivo conditions of a heartbeat. In addition, a flow rate of 60 rpm generated a range of 
wall shear stresses that were above 0.2 Pa and fell within the physiological range for capillary 
blood flow. When exposed to high flow rates the cells exhibited a low fluorescence intensity. 
The presence of a low intensity indicated that there were viable cells on the scaffolds but at a 
much lower cell magnitude than the Day 0 scaffold. The low resazurin output and 
immunostaining of the scaffold support the theory that either cells sheared off or there was 
shearing between the collagen layer and silk scaffold.  
Results from these trials showed that this flow rate caused the cells to shear off the 
scaffold. As a result, we reduced the flow rate to 10 rpm, which still accurately models early 
capillary development. These new trials resulted in the successful dynamic culture of an 
endothelial monolayer with the indication of accurate cell morphology and tight junction 
formation. The phalloidin-stained f-actin consistently surrounds each nucleus, suggesting that 
these tight junctions are forming to adhere the endothelial cells to each other.  
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CHAPTER 8 -- CONCLUSIONS AND RECOMMENDATIONS 
8.1 Conclusions 
 The goal of this project was to develop a 3D, perfusable endothelialized in vitro tumor 
model. The proposed solution incorporated a 10% lyophilized silk scaffold, resulting in a 
stiffness of approximately 8.6 kPa, allowing accurate endothelial cell growth and morphology. 
Endothelial cells were seeded onto the scaffold and statically cultured for three days in a 
monolayer, before being dynamically cultured for seven. Dynamic culture was achieved via the 
development of a closed loop perfusion bioreactor system. This system incorporated a 
peristaltic pump, which was chosen for its ability to control the flow rate and mimic in vivo 
flow through tumor capillaries.  
 Results of various trials proved that the perfusion bioreactor system was sterile and 
non-toxic to cells. Additionally, it proved that endothelial cells could be dynamically cultured 
on a silk scaffold for seven days using a flow rate of 10 rpm. Imaging from the Day 7 dynamic 
scaffolds showed that the cells were present and alive. While these scaffolds had a less 
confluent cell layer than the Day 7 static scaffolds, cell layers on both scaffolds were viable. In 
conclusion, we created a perfusion bioreactor system that resulted in a preliminary perfusable, 
humanized, endothelialized in vitro tumor model allowing for controlled fluid flow. 
 
8.2 Recommendations 
 While this project laid the groundwork for a more accurate in vitro tumor model to use 
in biological research, there are still areas that need improvement before implementation of this 
model. Future applications of this project include the co-culture of the silk scaffold with 
neuroblastoma cells. Neuroblastoma is a highly vascularized cancer type with a high likelihood 
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to metastasize. Additionally, it offers phenotypic diversity, heterogeneity, and an embryonal 
origin [73]. For these reasons, pediatric neuroblastoma is an exemplary model for solid tumors. 
Thus, co-culture of the current tumor model system with neuroblastoma cells would create an 
accurate in vitro cancer model for preclinical trial pharmaceutical testing. For this application, 
it would be important to ensure tight junction formation of the endothelial monolayer to restrict 
the transport of large molecules. 
 Additionally, future applications could collect cells that migrate or detach from the 
scaffold in the perfusion bioreactor to analyze them further. Trapping these cells would involve 
integration of a mechanism such as hydrodynamic trapping, dielectrophoresis and negative 
pressure traps [74]. These mechanisms are primarily used in microfluidics that could be 
applied to a perfusion bioreactor system. 
 Other recommendations to improve the perfusion bioreactor system include adding 
access points into the system. These access points would be beneficial to sample the cell 
culture media during trials in order to monitor pH and other nutrients essential for cell 
viability. This would ensure that the cells had a consistent, homeostatic environment in 
addition to having nutrients they need. These access points could also help to improve the 
dynamic culturing of cells to better mimic the monolayer achieved during static culture. 
However, these access points would need to be designed in such a way to ensure sterility of the 
media and closed loop system. 
 Lastly, recommendations for the silk scaffold include altering the scaffold geometry to 
better mimic in vivo conditions. The scaffold should be lyophilized around wires, which would 
create channels in the scaffold. The cells would then be seeded in the channels, which would 
require a rotational seeding device to ensure uniform channel seeding. However, seeding the 
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endothelial cells in this way would better represent flow in capillaries, making the model more 
accurate to in vivo conditions.  
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APPENDICES 
Appendix A: Stress/Strain Curves for Mechanical Testing of Silk Scaffolds 
Below are the stress/strain curves we obtained using an LTCM-100 machine with a 
Chatillon DF force gauge (Ametek, Inc.) to perform compression testing of various silk 
concentrations. Data was collected compressing the scaffold at a rate of 5.08 mm/min.  
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Appendix B: Resazurin Impact on Cell Viability and Proliferation Protocol 
1) Measure out resazurin powder and dilute in sterile PBS at a concentration of 0.15 
mg/mL. Wrap conical tube in aluminum foil or light sealed container in order to 
prevent damaging the fluorescence.  
2) Dilute resazurin solution 1:5 in warmed endothelial vascular growth media.  
3) Aspirate cell media from each well.  
4) Add the same volume of 0.15 mg/mL resazurin as removed cell media. In addition add 
resazurin to empty wells as blank control readings. Once added to the plate let it 
incubate for three hours at 37℃ and 5% CO2. 
5) Remove black 96 well plate from 60℃ oven.  
6) Remove 100 µl of resazurin media from each well and transfer to corresponding well in 
black 96-well plate. At this stage the testing is no longer sterile.  
7) Read plate on plate reader with the following protocol settings in place. 
 
Delay Between Repeats 0 s 
Measurement Height  8.00 mm 
Name of the Label  Alamar Blue 0.1 s  
Label Technology Prompt Fluorometry 
CW-Lamp Filter Name 544/15 
CW-lamp Filter Slot A8 
Emission Filter Name 590-20 
Emission Filter Slot A1 
Measurement Time 0.1 s 
Emission Aperture Normal  
CW-Lamp Energy 14848 
Second Measurement CW-Lamp Energy 0 
Emission Side Above 
CW-Lamp Control Stabilized Energy  
Excitation Aperture N/A 
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Appendix C: CD31 Staining Protocol  
Optimization and Validation Study:  
 
A) Protocol developed by Hannah Strobel and Dr. Marsha Rolle’s Lab 
Primary: Rabbit anti CD-31 monoclonal 1:50 (Abcam 28364) 
Secondary: Alexa-Fluor 568 goat anti-rabbit 1:400 (Invitrogen A11036) 
 
B) Protocol developed using antibodies from Dr. Raymond Page’s Lab 
Primary: PECAM Chemicon (1:50) 
Secondary: (1:400) 
 
Nuclear: Hoechst (1:6000 in distilled water)  
F-Actin- Phalloidin (1:40)  
 
Procedure for Coverslips: 
1) Aspirate cell media from each well carefully as not to disrupt cellular surface of the 
coverslip.  
2) Add 0.5 mL 4.% PFA to each well and allow to sit for 5-10 minutes to fix the 
endothelial culture.  
3) Wash 3x in PBS for 5 mins. 
4) Permeabilize the cells with 0.25% Triton X in PBS for 20 minutes. (4 mL for each 
coverslip)  
5) Block with 5% goat serum in PBS for 30 mins.  
6) Incubate in primary antibody overnight at 4℃. 
7) Wash 3x in PBS for 5 mins. 
8) Incubate in secondary antibody and Phalloidin for 1hr at room temperature.  
9) Wash 3x in PBS for 5 mins. 
10)  Add mounting gel to the slide to secure and preserve the sample.  
 
Procedure for Collagen Embedded Silk Scaffold (24 Well Plate): 
11) Aspirate cell media from each well carefully as not to disrupt cellular surface of the 
coverslip.  
12) Add 2 mL 4.% PFA to each well and allow to sit for 2 hours to allow for full infiltration 
into the scaffold to fix the cells.  
13) Wash 3x in PBS for 5 mins. 
14) Add stain at the following dilutions 
a) 1:250 Hoescht 
b) 1:20 Phalloidin  
c) 1:500 AdipoRed 
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d) 5% Triton 0.05% BSA in PBS 
15) Incubate in primary antibody overnight at 4℃. 
16) Wash 3x in PBS for 5 mins. 
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Appendix D: Silk Extraction Protocol 
Materials - Extraction 
1) Silk cocoons 
2) Stir bar 
3) 2 L glass beaker, hot plate 
4) 2 L plastic beaker 
5) Sodium carbonate 
6) Weigh boats 
7) Scale 
8) Milli-Q water (ultrapure water) 
9) Thermoresistant gloves 
  
  
Materials - Dissolving in LiBr 
1) Lithium bromide, weigh boat, scale 
2) 50 or 100 mL graduated cylinder 
3) 30 or 50 mL glass beaker and stir bar 
  
Materials - Dialysis 
1) Dialysis tubing, foam floats, elastic bands 
2) 1L water (plastic beaker) 
3) BD syringe, 18G needle 
  
Methods - Extraction 
1) Cut dried cocoons with scissors into dime-sized pieces and weigh 5g of it. 
2) Weigh 4.24 g of sodium carbonate.  
3) Prepare a glass beaker filled with 2 L of Milli-Q water and heat it up until boiling. 
4) Add the measured sodium carbonate to the boiling water and let it completely dissolve. 
5) Put the cocoon pieces in the boiling water and boil it for 30 minutes. Occasionally, 
poke the fibers with a spatula to promote good dispersion of fibroin.  
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Methods - Rinsing 
1) Throw away supernatant in the sink, and squeeze the extracted silk with a spatula 
2) Put it in a plastic beaker filled with 1-1.5 L of Milli-Q water. 
3) Keep it in the beaker for 20 minutes; occasionally rinse silk fibers by hand 
4) Change the water and do the same procedure another two times. 
5) After the third (3 times of each 20 minutes) wash, take out the silk, squeeze it well and 
then untie it by hands. 
6) Put in fume hood to air dry the silk at least for 12 hours. 
  
Methods - Dissolving in LiBr 
1) Prepare a 9.3 M LiBr solution.  
2) Make a 20% w/v solution of dried silk in 9.3 M LiBr solution (ex. add 1g fibers to 4 mL 
9.3 M LiBr solution) 
3) Let it dissolve in an oven at 60˚C for up to 4 hours. 
  
Methods - Dialysis 
1) Wet dialysis tubing in water for 2-3 minutes.  
2) Insert 12 mL of the silk-LiBr solution in a 3-12 mL dialysis tube and dialyze against 1 
L of MilliQ water. 
3) Change water after 1 hr, 3 hrs, 5-6 hrs (3 changes first day), next morning, and evening 
(2 changes second day), and the following day morning (1 change on the third day). 
Total water changes = 6 
  
Methods - Centrifugation 
1) Collect silk solution from the dialysis tubing. 
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2) Centrifuge for 20 minutes at 5-10˚C (9,000 rpm), 2 times. 
 
Methods – Concentration calculation 
1) Weigh an empty weighing boat (W1) 
2) Add 1 mL silk solution (measured accurately with a 1000 uM micropipetter) and record 
the weight (W2) 
3) Leave the weighing boat into a 60 ºC oven overnight 
4) Next day, weigh the weighing boat again (W3) 
5) The concentration of the silk solution (w/v) is: % = (W3-W1/W2-W1) x 100 
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Appendix E: Fluid Dynamics Calculations and Modeling for Bioreactor System 
The data collected from the biomaterial trial was inputted and fitted to a linear 
regression curve in order to quantify the relationship between the perfusion pump and the 
volumetric flow rate of the Swinnex. The bioreactor speed in rpm was inputted into the 
equation generated below in order to arrive at the proper volumetric flow rate in the scaffold. 
This volumetric flow rate served as the input for the initial boundary condition at the inlet of 
the half moon channel. 
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Appendix F: SolidWorks Flow Simulation Protocol 
1) Create SolidWorks model with relevant scaffold geometry.  
In the report above we modeled a hollow channel through the shape to match the scaffold 
geometry within the Swinnex. The image below shows the outer layer hidden to reflect the 
internal geometry.  
 
 
 
 
 
2)  
Go to SOLIDWORKS Add-Ins→ SOLIDWORKS Flow Simulation  
If the shape is not water tight you will be asked to close the structure to simulate fluid.  
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Go to Tools→Xpress Products→ Flow Xpress and it will guide you through a tutorial to set up 
your configuration and fluid medium. When you open the other flow simulator after it will 
prompt you to start a simulation with that model. Select yes.  
 
3) Right click on Boundary Conditions shown below and add in any boundary conditions to the 
system.  
 
  
  
133 
 
 
Once all input conditions were established the simulation was run using the newly available 
“Flow Simulation” tab shown below. 
 
 
Once the system runs calculations an additional set of tabs in the Flow Simulation tree will 
become available as shown below. 
 
 
The heat maps produced in this report can be produced by right clicking on surface plots and 
selecting shear stress as an option. This creates a heat map for shear stress but can be modified 
for other metrics as well for any selected face or surface. In addition the results can be exported 
to Excel for further analysis using the “Export Results” option.  
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Appendix G: ATCC TIME Endothelial Cells Passaging Protocol 
Volumes used in this protocol are for 75 cm2 flasks; proportionally reduce or increase amount 
of dissociation medium for culture vessels of other sizes. 
Note: Subculture when cultures are about 80% confluent. 
1) Remove and discard spent medium. 
2) Briefly rinse the cells with Dulbecco's Phosphate Buffered Saline (D-PBS, ATCC 30-
2200) and discard rinse solution. 
3) Add 2.0 to 3.0 mL room temperature Trypsin-EDTA for Primary Cells (ATCC PCS-
999-003) to the flask. Incubate at 37°C for 5 min (until cells have detached). 
4) Neutralize trypsin by adding an equal volume of room temperature 2% FBS in D-PBS. 
5) Transfer cells to a centrifuge tube. Rinse the flask with an additional room temperature 
2% FBS in D-PBS and pool into centrifuge tube with cells. 
6) Centrifuge cells at 0.2 x G for 10 min at room temperature. 
7) Remove supernatant. Resuspend pellet in 6.0 to 8.0 mL Complete Growth Medium. 
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 Appendix H: Silk Scaffold Seeding Protocol for Half Moon Geometry 
1) TIME endothelial cells are passaged according to protocol outlined in Appendix G.  
2) Cells were removed from suspension to have enough for 100,000 cells per scaffold.  
3) Cells were spun down at 0.2 x G  
4) Cells were resuspended so that each scaffold will have 100,000 cells in 10 µl drops.  
5) 200 µl of 2mg/ml collagen was added to the scaffold by pipetting slowly over the top 
surface.  Scaffolds were placed on Petri dish. 
6) Collagen was placed in incubator at 5% CO2 at 37 ℃ until it gelled. 
7) Once gelled 10 µl of suspension was added to the center of the scaffold slowly in a 
single drop.  
8) Cells were placed in the incubator at 5% CO2 at 37 ℃ for two hours to adhere.  
9) Scaffolds were removed from the Petri dish and placed in a 24-well plate and flooded 
with 2ml per well or until the scaffold was completely submerged. Media was added 
slowly to the side of the well to avoid shearing. 
10) Cells were maintained for 3 days before placement in the bioreactor.  
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Appendix I: Collagen Gel Formulation 
For 2 mg/mL collagen gel: 
1) Obtain Type 1 Rat Tail Collagen (Corning Product 3354236), 10X PBS, NaOH, and 
cell culture media. Keep cold on ice. 
2) In a 15 mL conical tube, combine 1.29 mL collagen and 0.2 mL 10X PBS. 
3) Add 0.35 mL cell culture media for use as a pH indicator. 
4) Add 5 μL NaOH at a time to a total of 17 μL, or until pink. Mix gently after each 
addition of NaOH. Keep cold. 
5) Once pink, add 143 μL (cold) cell culture media. Mix gently. 
6) Keep the mixture cold until it is ready to be gelled. Will gel in <30 minutes once added 
to the plate. 
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Appendix J: Media Composition  
Cells were cultured using ATCC Vascular Cell Basal Medium (ATCC PCS-100-030) and 
supplemented with VEGF growth kit (ATCC PCS-100-041). The following chart details the 
concentration of growth factors and additives in vascular growth medium. Phenol red and 
Penicillin Streptomycin were supplemented to the ATCC growth kit.  
 
Media Component  Final Concentration 
rh VEGF µ 5 ng/mL 
rh EGF 5 ng/mL 
rh FGF basic 5 ng/mL 
rh IGF-1 15 ng/mL 
L-glutamine 10 mM 
Heparin Sulfate 0.75 units/mL 
Hydrocortisone Hemmisuccinate 1 µg/mL 
Fetal Bovine Serum 5% 
Ascorbic Acid 50 µg/mL 
Penn-Strep 10,000 units/mL 
 
